<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.nature.com/articles/s43018-022-00418-6">Original</a>
    <h1>Cancer vaccines: the next immunotherapy frontier</h1>
    
    <div id="readability-page-1" class="page"><div data-track-component="outbound reference"><li data-counter="1."><p id="ref-CR1">Kosinska, A. D. et al. Synergy of therapeutic heterologous prime–boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. <i>Sci. Rep</i>. <b>9</b>, 10808 (2019).</p></li><li data-counter="2."><p id="ref-CR2">DeMaria, P. J. &amp; Bilusic, M. Cancer vaccines. <i>Hematol. Oncol. Clin. North Am.</i> <b>33</b>, 199–214 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.hoc.2018.12.001" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.hoc.2018.12.001" aria-label="Article reference 2" data-doi="10.1016/j.hoc.2018.12.001">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30832995" aria-label="PubMed reference 2">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Cancer%20vaccines&amp;journal=Hematol.%20Oncol.%20Clin.%20North%20Am.&amp;doi=10.1016%2Fj.hoc.2018.12.001&amp;volume=33&amp;pages=199-214&amp;publication_year=2019&amp;author=DeMaria%2CPJ&amp;author=Bilusic%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="3."><p id="ref-CR3">Old, L. J., Clarke, D. A. &amp; Benacerraf, B. Effect of Bacillus Calmette–Guérin infection on transplanted tumours in the mouse. <i>Nature</i> <b>184</b>, 291–292 (1959).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/184291a0" data-track-action="article reference" href="https://doi.org/10.1038%2F184291a0" aria-label="Article reference 3" data-doi="10.1038/184291a0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14428599" aria-label="PubMed reference 3">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20Bacillus%20Calmette%E2%80%93Gu%C3%A9rin%20infection%20on%20transplanted%20tumours%20in%20the%20mouse&amp;journal=Nature&amp;doi=10.1038%2F184291a0&amp;volume=184&amp;pages=291-292&amp;publication_year=1959&amp;author=Old%2CLJ&amp;author=Clarke%2CDA&amp;author=Benacerraf%2CB">
                    Google Scholar</a> 
                </p></li><li data-counter="4."><p id="ref-CR4">Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. <i>Nat. Med.</i> <b>25</b>, 814–824 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41591-019-0410-x" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-019-0410-x" aria-label="Article reference 4" data-doi="10.1038/s41591-019-0410-x">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXosFKhtb4%3D" aria-label="CAS reference 4">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30962585" aria-label="PubMed reference 4">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Systemic%20clinical%20tumor%20regressions%20and%20potentiation%20of%20PD1%20blockade%20with%20in%20situ%20vaccination&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0410-x&amp;volume=25&amp;pages=814-824&amp;publication_year=2019&amp;author=Hammerich%2CL">
                    Google Scholar</a> 
                </p></li><li data-counter="5."><p id="ref-CR5">Brody, J. D. et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. <i>J. Clin. Oncol.</i> <b>28</b>, 4324–4332 (2010).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2010.28.9793" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2010.28.9793" aria-label="Article reference 5" data-doi="10.1200/JCO.2010.28.9793">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20697067" aria-label="PubMed reference 5">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954133" aria-label="PubMed Central reference 5">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=In%20situ%20vaccination%20with%20a%20TLR9%20agonist%20induces%20systemic%20lymphoma%20regression%3A%20a%20phase%20I%2FII%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2010.28.9793&amp;volume=28&amp;pages=4324-4332&amp;publication_year=2010&amp;author=Brody%2CJD">
                    Google Scholar</a> 
                </p></li><li data-counter="6."><p id="ref-CR6">Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>N. Engl. J. Med.</i> <b>363</b>, 411–422 (2010).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1001294" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1001294" aria-label="Article reference 6" data-doi="10.1056/NEJMoa1001294">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVGlurrN" aria-label="CAS reference 6">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20818862" aria-label="PubMed reference 6">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Sipuleucel-T%20immunotherapy%20for%20castration-resistant%20prostate%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1001294&amp;volume=363&amp;pages=411-422&amp;publication_year=2010&amp;author=Kantoff%2CPW">
                    Google Scholar</a> 
                </p></li><li data-counter="7."><p id="ref-CR7">J, R. et al. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. <i>Blood</i> <b>58</b>, 141–152 (1981).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood.V58.1.141.141" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.V58.1.141.141" aria-label="Article reference 7" data-doi="10.1182/blood.V58.1.141.141">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Serotherapy%20of%20acute%20lymphoblastic%20leukemia%20with%20monoclonal%20antibody&amp;journal=Blood&amp;doi=10.1182%2Fblood.V58.1.141.141&amp;volume=58&amp;pages=141-152&amp;publication_year=1981&amp;author=J%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="8."><p id="ref-CR8">Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. <i>Clin. Cancer Res.</i> <b>14</b>, 3044–3051 (2008).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-07-4079" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-07-4079" aria-label="Article reference 8" data-doi="10.1158/1078-0432.CCR-07-4079">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXmtVCmtbw%3D" aria-label="CAS reference 8">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18483370" aria-label="PubMed reference 8">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20safety%20and%20pharmacokinetic%20study%20of%20CT-011%2C%20a%20humanized%20antibody%20interacting%20with%20PD-1%2C%20in%20patients%20with%20advanced%20hematologic%20malignancies&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-07-4079&amp;volume=14&amp;pages=3044-3051&amp;publication_year=2008&amp;author=Berger%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="9."><p id="ref-CR9">Gross, G., Waks, T. &amp; Eshhar, Z. Expression of immunoglobulin–T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. <i>Proc. Natl Acad. Sci. USA</i> <b>86</b>, 10024–10028 (1989).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1073/pnas.86.24.10024" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.86.24.10024" aria-label="Article reference 9" data-doi="10.1073/pnas.86.24.10024">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK3cXntFChsw%3D%3D" aria-label="CAS reference 9">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2513569" aria-label="PubMed reference 9">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC298636" aria-label="PubMed Central reference 9">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Expression%20of%20immunoglobulin%E2%80%93T-cell%20receptor%20chimeric%20molecules%20as%20functional%20receptors%20with%20antibody-type%20specificity&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.86.24.10024&amp;volume=86&amp;pages=10024-10028&amp;publication_year=1989&amp;author=Gross%2CG&amp;author=Waks%2CT&amp;author=Eshhar%2CZ">
                    Google Scholar</a> 
                </p></li><li data-counter="10."><p id="ref-CR10">Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. <i>N. Engl. J. Med.</i> <b>367</b>, 1187–1197 (2012).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1207506" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1207506" aria-label="Article reference 10" data-doi="10.1056/NEJMoa1207506">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhsVKhsLvK" aria-label="CAS reference 10">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22894553" aria-label="PubMed reference 10">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Increased%20survival%20with%20enzalutamide%20in%20prostate%20cancer%20after%20chemotherapy&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1207506&amp;volume=367&amp;pages=1187-1197&amp;publication_year=2012&amp;author=Scher%2CHI">
                    Google Scholar</a> 
                </p></li><li data-counter="11."><p id="ref-CR11">Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. <i>N. Engl. J. Med.</i> <b>363</b>, 711–723 (2010).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1003466" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1003466" aria-label="Article reference 11" data-doi="10.1056/NEJMoa1003466">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVCrtrbN" aria-label="CAS reference 11">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20525992" aria-label="PubMed reference 11">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297" aria-label="PubMed Central reference 11">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1003466&amp;volume=363&amp;pages=711-723&amp;publication_year=2010&amp;author=Hodi%2CFS">
                    Google Scholar</a> 
                </p></li><li data-counter="12."><p id="ref-CR12">Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma. <i>Nat. Med.</i> <b>5</b>, 1171–1177 (1999).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/13928" data-track-action="article reference" href="https://doi.org/10.1038%2F13928" aria-label="Article reference 12" data-doi="10.1038/13928">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1MXms1WktrY%3D" aria-label="CAS reference 12">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10502821" aria-label="PubMed reference 12">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Complete%20molecular%20remissions%20induced%20by%20patient-specific%20vaccination%20plus%20granulocyte%E2%80%93monocyte%20colony-stimulating%20factor%20against%20lymphoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2F13928&amp;volume=5&amp;pages=1171-1177&amp;publication_year=1999&amp;author=Bendandi%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="13."><p id="ref-CR13">Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>346</b>, 235–242 (2002).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa011795" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa011795" aria-label="Article reference 13" data-doi="10.1056/NEJMoa011795">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38XmslGgsw%3D%3D" aria-label="CAS reference 13">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11807147" aria-label="PubMed reference 13">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=CHOP%20chemotherapy%20plus%20rituximab%20compared%20with%20CHOP%20alone%20in%20elderly%20patients%20with%20diffuse%20large-B-cell%20lymphoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa011795&amp;volume=346&amp;pages=235-242&amp;publication_year=2002&amp;author=Coiffier%2CB">
                    Google Scholar</a> 
                </p></li><li data-counter="14."><p id="ref-CR14">Melief, C. J., van Hall, T., Arens, R., Ossendorp, F. &amp; van der Burg, S. H. Therapeutic cancer vaccines. <i>J. Clin. Invest.</i> <b>125</b>, 3401–3412 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1172/JCI80009" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI80009" aria-label="Article reference 14" data-doi="10.1172/JCI80009">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26214521" aria-label="PubMed reference 14">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588240" aria-label="PubMed Central reference 14">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20cancer%20vaccines&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI80009&amp;volume=125&amp;pages=3401-3412&amp;publication_year=2015&amp;author=Melief%2CCJ&amp;author=Hall%2CT&amp;author=Arens%2CR&amp;author=Ossendorp%2CF&amp;author=Burg%2CSH">
                    Google Scholar</a> 
                </p></li><li data-counter="15."><p id="ref-CR15">Malekzadeh, P. et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens. <i>Clin. Cancer Res.</i> <b>26</b>, 1267–1276 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-19-1874" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-19-1874" aria-label="Article reference 15" data-doi="10.1158/1078-0432.CCR-19-1874">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvValsLfL" aria-label="CAS reference 15">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31996390" aria-label="PubMed reference 15">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424598" aria-label="PubMed Central reference 15">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Antigen%20experienced%20T%20cells%20from%20peripheral%20blood%20recognize%20p53%20neoantigens&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-1874&amp;volume=26&amp;pages=1267-1276&amp;publication_year=2020&amp;author=Malekzadeh%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="16."><p id="ref-CR16">Jung, S. et al. In vivo depletion of CD11c<sup>+</sup> dendritic cells abrogates priming of CD8<sup>+</sup> T cells by exogenous cell-associated antigens. <i>Immunity</i> <b>17</b>, 211–220 (2002).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S1074-7613(02)00365-5" data-track-action="article reference" href="https://doi.org/10.1016%2FS1074-7613%2802%2900365-5" aria-label="Article reference 16" data-doi="10.1016/S1074-7613(02)00365-5">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38Xms12jsr8%3D" aria-label="CAS reference 16">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12196292" aria-label="PubMed reference 16">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689299" aria-label="PubMed Central reference 16">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=In%20vivo%20depletion%20of%20CD11c%2B%20dendritic%20cells%20abrogates%20priming%20of%20CD8%2B%20T%20cells%20by%20exogenous%20cell-associated%20antigens&amp;journal=Immunity&amp;doi=10.1016%2FS1074-7613%2802%2900365-5&amp;volume=17&amp;pages=211-220&amp;publication_year=2002&amp;author=Jung%2CS">
                    Google Scholar</a> 
                </p></li><li data-counter="17."><p id="ref-CR17">Salmon, H. et al. Expansion and activation of CD103<sup>+</sup> dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. <i>Immunity</i> <b>44</b>, 924–938 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2016.03.012" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2016.03.012" aria-label="Article reference 17" data-doi="10.1016/j.immuni.2016.03.012">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XmsVehsLw%3D" aria-label="CAS reference 17">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27096321" aria-label="PubMed reference 17">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980762" aria-label="PubMed Central reference 17">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Expansion%20and%20activation%20of%20CD103%2B%20dendritic%20cell%20progenitors%20at%20the%20tumor%20site%20enhances%20tumor%20responses%20to%20therapeutic%20PD-L1%20and%20BRAF%20inhibition&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2016.03.012&amp;volume=44&amp;pages=924-938&amp;publication_year=2016&amp;author=Salmon%2CH">
                    Google Scholar</a> 
                </p></li><li data-counter="18."><p id="ref-CR18">Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8α<sup>+</sup> dendritic cells in cytotoxic T cell immunity. <i>Science</i> <b>322</b>, 1097–1100 (2008).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/science.1164206" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.1164206" aria-label="Article reference 18" data-doi="10.1126/science.1164206">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXhtlGhu7fF" aria-label="CAS reference 18">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19008445" aria-label="PubMed reference 18">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756611" aria-label="PubMed Central reference 18">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Batf3%20deficiency%20reveals%20a%20critical%20role%20for%20CD8%CE%B1%2B%20dendritic%20cells%20in%20cytotoxic%20T%20cell%20immunity&amp;journal=Science&amp;doi=10.1126%2Fscience.1164206&amp;volume=322&amp;pages=1097-1100&amp;publication_year=2008&amp;author=Hildner%2CK">
                    Google Scholar</a> 
                </p></li><li data-counter="19."><p id="ref-CR19">Katanasaka, Y. et al. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. <i>Mol. Cancer</i> <b>12</b>, 31 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/1476-4598-12-31" data-track-action="article reference" href="https://doi.org/10.1186%2F1476-4598-12-31" aria-label="Article reference 19" data-doi="10.1186/1476-4598-12-31">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXotFCmsro%3D" aria-label="CAS reference 19">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23617883" aria-label="PubMed reference 19">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641008" aria-label="PubMed Central reference 19">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Epidermal%20growth%20factor%20receptor%20variant%20type%20III%20markedly%20accelerates%20angiogenesis%20and%20tumor%20growth%20via%20inducing%20c-myc%20mediated%20angiopoietin-like%204%20expression%20in%20malignant%20glioma&amp;journal=Mol.%20Cancer&amp;doi=10.1186%2F1476-4598-12-31&amp;volume=12&amp;publication_year=2013&amp;author=Katanasaka%2CY">
                    Google Scholar</a> 
                </p></li><li data-counter="20."><p id="ref-CR20">Taberna, M. et al. Human papillomavirus-related oropharyngeal cancer. <i>Ann. Oncol.</i> <b>28</b>, 2386–2398 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/annonc/mdx304" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdx304" aria-label="Article reference 20" data-doi="10.1093/annonc/mdx304">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1cjgtFCqtg%3D%3D" aria-label="CAS reference 20">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28633362" aria-label="PubMed reference 20">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Human%20papillomavirus-related%20oropharyngeal%20cancer&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx304&amp;volume=28&amp;pages=2386-2398&amp;publication_year=2017&amp;author=Taberna%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="21."><p id="ref-CR21">Qi, X. W. et al. Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. <i>Sci. Rep.</i> <b>5</b>, 8924 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/srep08924" data-track-action="article reference" href="https://doi.org/10.1038%2Fsrep08924" aria-label="Article reference 21" data-doi="10.1038/srep08924">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFKhur3K" aria-label="CAS reference 21">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25748047" aria-label="PubMed reference 21">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352850" aria-label="PubMed Central reference 21">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Wilms%E2%80%99%20tumor%201%20%28WT1%29%20expression%20and%20prognosis%20in%20solid%20cancer%20patients%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=Sci.%20Rep.&amp;doi=10.1038%2Fsrep08924&amp;volume=5&amp;publication_year=2015&amp;author=Qi%2CXW">
                    Google Scholar</a> 
                </p></li><li data-counter="22."><p id="ref-CR22">Chong, C., Coukos, G. &amp; Bassani-Sternberg, M. Identification of tumor antigens with immunopeptidomics. <i>Nat. Biotechnol.</i> <b>40</b>, 175–188 (2021).</p></li><li data-counter="23."><p id="ref-CR23">Cheever, M. A. et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. <i>Clin. Cancer Res.</i> <b>15</b>, 5323–5337 (2009).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-09-0737" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-09-0737" aria-label="Article reference 23" data-doi="10.1158/1078-0432.CCR-09-0737">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19723653" aria-label="PubMed reference 23">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779623" aria-label="PubMed Central reference 23">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20prioritization%20of%20cancer%20antigens%3A%20a%20National%20Cancer%20Institute%20pilot%20project%20for%20the%20acceleration%20of%20translational%20research&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-09-0737&amp;volume=15&amp;pages=5323-5337&amp;publication_year=2009&amp;author=Cheever%2CMA">
                    Google Scholar</a> 
                </p></li><li data-counter="24."><p id="ref-CR24">Tsao, S. W., Tramoutanis, G., Dawson, C. W., Lo, A. K. F. &amp; Huang, D. P. The significance of LMP1 expression in nasopharyngeal carcinoma. <i>Semin. Cancer Biol.</i> <b>12</b>, 473–487 (2002).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S1044579X02000901" data-track-action="article reference" href="https://doi.org/10.1016%2FS1044579X02000901" aria-label="Article reference 24" data-doi="10.1016/S1044579X02000901">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38Xosl2nsr0%3D" aria-label="CAS reference 24">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12450733" aria-label="PubMed reference 24">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20significance%20of%20LMP1%20expression%20in%20nasopharyngeal%20carcinoma&amp;journal=Semin.%20Cancer%20Biol.&amp;doi=10.1016%2FS1044579X02000901&amp;volume=12&amp;pages=473-487&amp;publication_year=2002&amp;author=Tsao%2CSW&amp;author=Tramoutanis%2CG&amp;author=Dawson%2CCW&amp;author=Lo%2CAKF&amp;author=Huang%2CDP">
                    Google Scholar</a> 
                </p></li><li data-counter="25."><p id="ref-CR25">Lin, M. C., Lin, Y. C., Chen, S. T., Young, T. H. &amp; Lou, P. J. Therapeutic vaccine targeting Epstein–Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo. <i>BMC Cancer</i> <b>17</b>, 18 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/s12885-016-3027-1" data-track-action="article reference" href="https://doi.org/10.1186%2Fs12885-016-3027-1" aria-label="Article reference 25" data-doi="10.1186/s12885-016-3027-1">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28056887" aria-label="PubMed reference 25">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216543" aria-label="PubMed Central reference 25">PubMed Central</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXjs12nt7Y%3D" aria-label="CAS reference 25">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20vaccine%20targeting%20Epstein%E2%80%93Barr%20virus%20latent%20protein%2C%20LMP1%2C%20suppresses%20LMP1-expressing%20tumor%20growth%20and%20metastasis%20in%20vivo&amp;journal=BMC%20Cancer&amp;doi=10.1186%2Fs12885-016-3027-1&amp;volume=17&amp;publication_year=2017&amp;author=Lin%2CMC&amp;author=Lin%2CYC&amp;author=Chen%2CST&amp;author=Young%2CTH&amp;author=Lou%2CPJ">
                    Google Scholar</a> 
                </p></li><li data-counter="26."><p id="ref-CR26">Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. <i>J. Clin. Oncol.</i> <b>32</b>, 798–808 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2013.51.5304" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2013.51.5304" aria-label="Article reference 26" data-doi="10.1200/JCO.2013.51.5304">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXnsl2iur0%3D" aria-label="CAS reference 26">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24344220" aria-label="PubMed reference 26">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Sustained%20complete%20responses%20in%20patients%20with%20lymphoma%20receiving%20autologous%20cytotoxic%20T%20lymphocytes%20targeting%20Epstein%E2%80%93Barr%20virus%20latent%20membrane%20proteins&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2013.51.5304&amp;volume=32&amp;pages=798-808&amp;publication_year=2014&amp;author=Bollard%2CCM">
                    Google Scholar</a> 
                </p></li><li data-counter="27."><p id="ref-CR27">Chia, W. K. et al. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1–LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. <i>Ann. Oncol.</i> <b>23</b>, 997–1005 (2012).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/annonc/mdr341" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdr341" aria-label="Article reference 27" data-doi="10.1093/annonc/mdr341">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC38zltF2huw%3D%3D" aria-label="CAS reference 27">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21821548" aria-label="PubMed reference 27">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20II%20study%20evaluating%20the%20safety%20and%20efficacy%20of%20an%20adenovirus-%CE%94LMP1%E2%80%93LMP2%20transduced%20dendritic%20cell%20vaccine%20in%20patients%20with%20advanced%20metastatic%20nasopharyngeal%20carcinoma&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdr341&amp;volume=23&amp;pages=997-1005&amp;publication_year=2012&amp;author=Chia%2CWK">
                    Google Scholar</a> 
                </p></li><li data-counter="28."><p id="ref-CR28">Taylor, G. S. et al. A recombinant modified vaccinia Ankara vaccine encoding Epstein–Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. <i>Clin. Cancer Res.</i> <b>20</b>, 5009–5022 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-14-1122-T" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-14-1122-T" aria-label="Article reference 28" data-doi="10.1158/1078-0432.CCR-14-1122-T">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhs12gtbzN" aria-label="CAS reference 28">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25124688" aria-label="PubMed reference 28">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340506" aria-label="PubMed Central reference 28">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20recombinant%20modified%20vaccinia%20Ankara%20vaccine%20encoding%20Epstein%E2%80%93Barr%20virus%20%28EBV%29%20target%20antigens%3A%20a%20phase%20I%20trial%20in%20UK%20patients%20with%20EBV-positive%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-14-1122-T&amp;volume=20&amp;pages=5009-5022&amp;publication_year=2014&amp;author=Taylor%2CGS">
                    Google Scholar</a> 
                </p></li><li data-counter="29."><p id="ref-CR29">Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. <i>N. Engl. J. Med.</i> <b>361</b>, 1838–1847 (2009).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa0810097" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa0810097" aria-label="Article reference 29" data-doi="10.1056/NEJMoa0810097">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhtl2jurvO" aria-label="CAS reference 29">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19890126" aria-label="PubMed reference 29">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccination%20against%20HPV-16%20oncoproteins%20for%20vulvar%20intraepithelial%20neoplasia&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa0810097&amp;volume=361&amp;pages=1838-1847&amp;publication_year=2009&amp;author=Kenter%2CGG">
                    Google Scholar</a> 
                </p></li><li data-counter="30."><p id="ref-CR30">Massarelli, E. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. <i>JAMA Oncol.</i> <b>5</b>, 67–73 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamaoncol.2018.4051" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaoncol.2018.4051" aria-label="Article reference 30" data-doi="10.1001/jamaoncol.2018.4051">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30267032" aria-label="PubMed reference 30">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Combining%20immune%20checkpoint%20blockade%20and%20tumor-specific%20vaccine%20for%20patients%20with%20incurable%20human%20papillomavirus%2016-related%20cancer%3A%20a%20phase%202%20clinical%20trial&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2018.4051&amp;volume=5&amp;pages=67-73&amp;publication_year=2019&amp;author=Massarelli%2CE">
                    Google Scholar</a> 
                </p></li><li data-counter="31."><p id="ref-CR31">Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet</i> <b>386</b>, 2078–2088 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(15)00239-1" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2815%2900239-1" aria-label="Article reference 31" data-doi="10.1016/S0140-6736(15)00239-1">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFaru7jF" aria-label="CAS reference 31">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26386540" aria-label="PubMed reference 31">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888059" aria-label="PubMed Central reference 31">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20efficacy%2C%20and%20immunogenicity%20of%20VGX-3100%2C%20a%20therapeutic%20synthetic%20DNA%20vaccine%20targeting%20human%20papillomavirus%2016%20and%2018%20E6%20and%20E7%20proteins%20for%20cervical%20intraepithelial%20neoplasia%202%2F3%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%20phase%202b%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2815%2900239-1&amp;volume=386&amp;pages=2078-2088&amp;publication_year=2015&amp;author=Trimble%2CCL">
                    Google Scholar</a> 
                </p></li><li data-counter="32."><p id="ref-CR32">Kim, T. J. et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. <i>Nat. Commun.</i> <b>5</b>, 5317 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/ncomms6317" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms6317" aria-label="Article reference 32" data-doi="10.1038/ncomms6317">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXksVCjs7g%3D" aria-label="CAS reference 32">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25354725" aria-label="PubMed reference 32">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Clearance%20of%20persistent%20HPV%20infection%20and%20cervical%20lesion%20by%20therapeutic%20DNA%20vaccine%20in%20CIN3%20patients&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms6317&amp;volume=5&amp;publication_year=2014&amp;author=Kim%2CTJ">
                    Google Scholar</a> 
                </p></li><li data-counter="33."><p id="ref-CR33">Harper, D. M. et al. The efficacy and safety of tipapkinogen sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: randomized controlled phase II trial with 2.5 years of follow-up. <i>Gynecol. Oncol.</i> <b>153</b>, 521–529 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ygyno.2019.03.250" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ygyno.2019.03.250" aria-label="Article reference 33" data-doi="10.1016/j.ygyno.2019.03.250">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30955915" aria-label="PubMed reference 33">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20efficacy%20and%20safety%20of%20tipapkinogen%20sovacivec%20therapeutic%20HPV%20vaccine%20in%20cervical%20intraepithelial%20neoplasia%20grades%202%20and%203%3A%20randomized%20controlled%20phase%20II%20trial%20with%202.5%20years%20of%20follow-up&amp;journal=Gynecol.%20Oncol.&amp;doi=10.1016%2Fj.ygyno.2019.03.250&amp;volume=153&amp;pages=521-529&amp;publication_year=2019&amp;author=Harper%2CDM">
                    Google Scholar</a> 
                </p></li><li data-counter="34."><p id="ref-CR34">O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. <i>Sci. Transl. Med.</i> <b>9</b>, eaaa0984 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.aaa0984" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.aaa0984" aria-label="Article reference 34" data-doi="10.1126/scitranslmed.aaa0984">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28724573" aria-label="PubMed reference 34">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762203" aria-label="PubMed Central reference 34">PubMed Central</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVSgtrnO" aria-label="CAS reference 34">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20single%20dose%20of%20peripherally%20infused%20EGFRvIII-directed%20CAR%20T%20cells%20mediates%20antigen%20loss%20and%20induces%20adaptive%20resistance%20in%20patients%20with%20recurrent%20glioblastoma&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.aaa0984&amp;volume=9&amp;publication_year=2017&amp;author=O%E2%80%99Rourke%2CDM">
                    Google Scholar</a> 
                </p></li><li data-counter="35."><p id="ref-CR35">Schuster, J. et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro Oncol.</i> <b>17</b>, 854–861 (2015).</p></li><li data-counter="36."><p id="ref-CR36">Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncol.</i> <b>18</b>, 1373–1385 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(17)30517-X" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2817%2930517-X" aria-label="Article reference 36" data-doi="10.1016/S1470-2045(17)30517-X">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlOrt73N" aria-label="CAS reference 36">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28844499" aria-label="PubMed reference 36">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Rindopepimut%20with%20temozolomide%20for%20patients%20with%20newly%20diagnosed%2C%20EGFRvIII-expressing%20glioblastoma%20%28ACT%20IV%29%3A%20a%20randomised%2C%20double-blind%2C%20international%20phase%203%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2817%2930517-X&amp;volume=18&amp;pages=1373-1385&amp;publication_year=2017&amp;author=Weller%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="37."><p id="ref-CR37">Reardon, D. A. et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. <i>Clin. Cancer Res.</i> <b>26</b>, 1586–1594 (2020).</p></li><li data-counter="38."><p id="ref-CR38">Oka, Y. et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. <i>Proc. Natl Acad. Sci. USA</i> <b>101</b>, 13885–13890 (2004).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1073/pnas.0405884101" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.0405884101" aria-label="Article reference 38" data-doi="10.1073/pnas.0405884101">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2cXotVygtbY%3D" aria-label="CAS reference 38">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15365188" aria-label="PubMed reference 38">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC518848" aria-label="PubMed Central reference 38">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Induction%20of%20WT1%20%28Wilms%E2%80%99%20tumor%20gene%29-specific%20cytotoxic%20T%20lymphocytes%20by%20WT1%20peptide%20vaccine%20and%20the%20resultant%20cancer%20regression&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0405884101&amp;volume=101&amp;pages=13885-13890&amp;publication_year=2004&amp;author=Oka%2CY">
                    Google Scholar</a> 
                </p></li><li data-counter="39."><p id="ref-CR39">Maslak, P. G. et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. <i>Blood Adv.</i> <b>2</b>, 224–234 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/bloodadvances.2017014175" data-track-action="article reference" href="https://doi.org/10.1182%2Fbloodadvances.2017014175" aria-label="Article reference 39" data-doi="10.1182/bloodadvances.2017014175">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXlsFOqt7o%3D" aria-label="CAS reference 39">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29386195" aria-label="PubMed reference 39">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812332" aria-label="PubMed Central reference 39">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%202%20trial%20of%20a%20multivalent%20WT1%20peptide%20vaccine%20%28galinpepimut-S%29%20in%20acute%20myeloid%20leukemia&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2017014175&amp;volume=2&amp;pages=224-234&amp;publication_year=2018&amp;author=Maslak%2CPG">
                    Google Scholar</a> 
                </p></li><li data-counter="40."><p id="ref-CR40">Keilholz, U. et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. <i>Blood</i> <b>113</b>, 6541–6548 (2009).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood-2009-02-202598" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2009-02-202598" aria-label="Article reference 40" data-doi="10.1182/blood-2009-02-202598">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXotlWrurk%3D" aria-label="CAS reference 40">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19389880" aria-label="PubMed reference 40">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20clinical%20and%20immunologic%20phase%202%20trial%20of%20Wilms%20tumor%20gene%20product%201%20%28WT1%29%20peptide%20vaccination%20in%20patients%20with%20AML%20and%20MDS&amp;journal=Blood&amp;doi=10.1182%2Fblood-2009-02-202598&amp;volume=113&amp;pages=6541-6548&amp;publication_year=2009&amp;author=Keilholz%2CU">
                    Google Scholar</a> 
                </p></li><li data-counter="41."><p id="ref-CR41">Anguille, S. et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. <i>Blood</i> <b>130</b>, 1713–1721 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood-2017-04-780155" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2017-04-780155" aria-label="Article reference 41" data-doi="10.1182/blood-2017-04-780155">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhs1elt7jO" aria-label="CAS reference 41">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28830889" aria-label="PubMed reference 41">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649080" aria-label="PubMed Central reference 41">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Dendritic%20cell%20vaccination%20as%20postremission%20treatment%20to%20prevent%20or%20delay%20relapse%20in%20acute%20myeloid%20leukemia&amp;journal=Blood&amp;doi=10.1182%2Fblood-2017-04-780155&amp;volume=130&amp;pages=1713-1721&amp;publication_year=2017&amp;author=Anguille%2CS">
                    Google Scholar</a> 
                </p></li><li data-counter="42."><p id="ref-CR42">Thomas, R. et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. <i>Front. Immunol.</i> <b>9</b>, 947 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fimmu.2018.00947" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2018.00947" aria-label="Article reference 42" data-doi="10.3389/fimmu.2018.00947">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29770138" aria-label="PubMed reference 42">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941317" aria-label="PubMed Central reference 42">PubMed Central</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXit1GlsrjK" aria-label="CAS reference 42">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=NY-ESO-1%20based%20immunotherapy%20of%20cancer%3A%20current%20perspectives&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2018.00947&amp;volume=9&amp;publication_year=2018&amp;author=Thomas%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="43."><p id="ref-CR43">D’angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259T cells in synovial sarcoma. <i>Cancer Discov.</i> <b>8</b>, 944–957 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-17-1417" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-17-1417" aria-label="Article reference 43" data-doi="10.1158/2159-8290.CD-17-1417">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29891538" aria-label="PubMed reference 43">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092079" aria-label="PubMed Central reference 43">PubMed Central</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVarsbfK" aria-label="CAS reference 43">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Antitumor%20activity%20associated%20with%20prolonged%20persistence%20of%20adoptively%20transferred%20NY-ESO-1c259T%20cells%20in%20synovial%20sarcoma&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-17-1417&amp;volume=8&amp;pages=944-957&amp;publication_year=2018&amp;author=D%E2%80%99angelo%2CSP">
                    Google Scholar</a> 
                </p></li><li data-counter="44."><p id="ref-CR44">Karbach, J. et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. <i>Clin. Cancer Res.</i> <b>17</b>, 861–870 (2011).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-10-1811" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-10-1811" aria-label="Article reference 44" data-doi="10.1158/1078-0432.CCR-10-1811">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXitVWjs7g%3D" aria-label="CAS reference 44">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21163871" aria-label="PubMed reference 44">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficient%20in%20vivo%20priming%20by%20vaccination%20with%20recombinant%20NY-ESO-1%20protein%20and%20CpG%20in%20antigen%20naive%20prostate%20cancer%20patients&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-10-1811&amp;volume=17&amp;pages=861-870&amp;publication_year=2011&amp;author=Karbach%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="45."><p id="ref-CR45">Dhodapkar, M. V. et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. <i>Sci. Transl. Med.</i> <b>6</b>, 232–251 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.3008068" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.3008068" aria-label="Article reference 45" data-doi="10.1126/scitranslmed.3008068">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXht1KntL7N" aria-label="CAS reference 45">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Induction%20of%20antigen-specific%20immunity%20with%20a%20vaccine%20targeting%20NY-ESO-1%20to%20the%20dendritic%20cell%20receptor%20DEC-205&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.3008068&amp;volume=6&amp;pages=232-251&amp;publication_year=2014&amp;author=Dhodapkar%2CMV">
                    Google Scholar</a> 
                </p></li><li data-counter="46."><p id="ref-CR46">Bhardwaj, N. et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. <i>Nat. Cancer</i> <b>1</b>, 1204–1217 (2020).</p></li><li data-counter="47."><p id="ref-CR47">Vansteenkiste, J. et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. <i>J. Clin. Oncol.</i> <b>31</b>, 2396–2403 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2012.43.7103" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2012.43.7103" aria-label="Article reference 47" data-doi="10.1200/JCO.2012.43.7103">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1GhtLrF" aria-label="CAS reference 47">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23715567" aria-label="PubMed reference 47">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Adjuvant%20MAGE-A3%20immunotherapy%20in%20resected%20non-small-cell%20lung%20cancer%3A%20phase%20II%20randomized%20study%20results&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2012.43.7103&amp;volume=31&amp;pages=2396-2403&amp;publication_year=2013&amp;author=Vansteenkiste%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="48."><p id="ref-CR48">Kruit, W. H. J. et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>J. Clin. Oncol.</i> <b>31</b>, 2413–2420 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2012.43.7111" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2012.43.7111" aria-label="Article reference 48" data-doi="10.1200/JCO.2012.43.7111">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1GhtLvF" aria-label="CAS reference 48">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23715572" aria-label="PubMed reference 48">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=Selection%20of%20immunostimulant%20AS15%20for%20active%20immunization%20with%20MAGE-A3%20protein%3A%20results%20of%20a%20randomized%20phase%20II%20study%20of%20the%20European%20Organisation%20for%20Research%20and%20Treatment%20of%20Cancer%20Melanoma%20Group%20in%20Metastatic%20Melanoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2012.43.7111&amp;volume=31&amp;pages=2413-2420&amp;publication_year=2013&amp;author=Kruit%2CWHJ">
                    Google Scholar</a> 
                </p></li><li data-counter="49."><p id="ref-CR49">Dreno, B. et al. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> <b>19</b>, 916–929 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(18)30254-7" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2818%2930254-7" aria-label="Article reference 49" data-doi="10.1016/S1470-2045(18)30254-7">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtFyqurnK" aria-label="CAS reference 49">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29908991" aria-label="PubMed reference 49">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=MAGE-A3%20immunotherapeutic%20as%20adjuvant%20therapy%20for%20patients%20with%20resected%2C%20MAGE-A3-positive%2C%20stage%20III%20melanoma%20%28DERMA%29%3A%20a%20double-blind%2C%20randomised%2C%20placebo-controlled%2C%20phase%203%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2818%2930254-7&amp;volume=19&amp;pages=916-929&amp;publication_year=2018&amp;author=Dreno%2CB">
                    Google Scholar</a> 
                </p></li><li data-counter="50."><p id="ref-CR50">Vansteenkiste, J. F. et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> <b>17</b>, 822–835 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(16)00099-1" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2816%2900099-1" aria-label="Article reference 50" data-doi="10.1016/S1470-2045(16)00099-1">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XntVCmt78%3D" aria-label="CAS reference 50">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27132212" aria-label="PubMed reference 50">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20the%20MAGE-A3%20cancer%20immunotherapeutic%20as%20adjuvant%20therapy%20in%20patients%20with%20resected%20MAGE-A3-positive%20non-small-cell%20lung%20cancer%20%28MAGRIT%29%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%203%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2816%2900099-1&amp;volume=17&amp;pages=822-835&amp;publication_year=2016&amp;author=Vansteenkiste%2CJF">
                    Google Scholar</a> 
                </p></li><li data-counter="51."><p id="ref-CR51">L, S. et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. <i>Cancer Res.</i> <b>64</b>, 9167–9171 (2004).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-04-1442" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-04-1442" aria-label="Article reference 51" data-doi="10.1158/0008-5472.CAN-04-1442">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Intratumor%20heterogeneity%20of%20cancer%2Ftestis%20antigens%20expression%20in%20human%20cutaneous%20melanoma%20is%20methylation-regulated%20and%20functionally%20reverted%20by%205-aza-2%E2%80%B2-deoxycytidine&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-04-1442&amp;volume=64&amp;pages=9167-9171&amp;publication_year=2004&amp;author=L%2CS">
                    Google Scholar</a> 
                </p></li><li data-counter="52."><p id="ref-CR52">Besse, B. et al. Activity of OSE-2101 in HLA-A2<sup>+</sup> non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): final results of phase III Atalante-1 randomised trial. In <i>ESMO Congress</i> S1283–S1346 (Annals of Oncology, 2021).</p></li><li data-counter="53."><p id="ref-CR53">Slingluff, C. L. et al. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. <i>J. Immunother. Cancer</i> <b>9</b>, e003272 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1136/jitc-2021-003272" data-track-action="article reference" href="https://doi.org/10.1136%2Fjitc-2021-003272" aria-label="Article reference 53" data-doi="10.1136/jitc-2021-003272">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34599031" aria-label="PubMed reference 53">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488725" aria-label="PubMed Central reference 53">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=Multicenter%2C%20double-blind%2C%20placebo-controlled%20trial%20of%20seviprotimut-L%20polyvalent%20melanoma%20vaccine%20in%20patients%20with%20post-resection%20melanoma%20at%20high%20risk%20of%20recurrence&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1136%2Fjitc-2021-003272&amp;volume=9&amp;publication_year=2021&amp;author=Slingluff%2CCL">
                    Google Scholar</a> 
                </p></li><li data-counter="54."><p id="ref-CR54">Mittendorf, E. A. et al. Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. <i>Clin. Cancer Res.</i> <b>25</b>, 4248–4254 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-18-2867" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-18-2867" aria-label="Article reference 54" data-doi="10.1158/1078-0432.CCR-18-2867">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhs1Smsb7F" aria-label="CAS reference 54">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31036542" aria-label="PubMed reference 54">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20analysis%20of%20nelipepimut-S%20vaccine%20to%20prevent%20breast%20cancer%20recurrence%3A%20a%20randomized%2C%20multicenter%2C%20phase%20III%20clinical%20trial&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-2867&amp;volume=25&amp;pages=4248-4254&amp;publication_year=2019&amp;author=Mittendorf%2CEA">
                    Google Scholar</a> 
                </p></li><li data-counter="55."><p id="ref-CR55">Mittendorf, E. A. et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. <i>Ann. Oncol.</i> <b>27</b>, 1241–1248 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/annonc/mdw150" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdw150" aria-label="Article reference 55" data-doi="10.1093/annonc/mdw150">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC28flt1yqsA%3D%3D" aria-label="CAS reference 55">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27029708" aria-label="PubMed reference 55">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922316" aria-label="PubMed Central reference 55">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=Primary%20analysis%20of%20a%20prospective%2C%20randomized%2C%20single-blinded%20phase%20II%20trial%20evaluating%20the%20HER2%20peptide%20AE37%20vaccine%20in%20breast%20cancer%20patients%20to%20prevent%20recurrence&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdw150&amp;volume=27&amp;pages=1241-1248&amp;publication_year=2016&amp;author=Mittendorf%2CEA">
                    Google Scholar</a> 
                </p></li><li data-counter="56."><p id="ref-CR56">Knutson, K. L., Schiffman, K. &amp; Disis, M. L. Immunization with a HER-2/Neu helper peptide vaccine generates HER-2/Neu CD8 T-cell immunity in cancer patients. <i>J. Clin. Invest.</i> <b>107</b>, 477–484 (2001).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1172/JCI11752" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI11752" aria-label="Article reference 56" data-doi="10.1172/JCI11752">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD3MXhtlWktb8%3D" aria-label="CAS reference 56">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11181647" aria-label="PubMed reference 56">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC199268" aria-label="PubMed Central reference 56">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunization%20with%20a%20HER-2%2FNeu%20helper%20peptide%20vaccine%20generates%20HER-2%2FNeu%20CD8%20T-cell%20immunity%20in%20cancer%20patients&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI11752&amp;volume=107&amp;pages=477-484&amp;publication_year=2001&amp;author=Knutson%2CKL&amp;author=Schiffman%2CK&amp;author=Disis%2CML">
                    Google Scholar</a> 
                </p></li><li data-counter="57."><p id="ref-CR57">RLB, C. &amp; BJ, C. Clinical development of immunotherapies for HER2<sup>+</sup> breast cancer: a review of HER2-directed monoclonal antibodies and beyond. <i>NPJ Breast Cancer</i> <b>6</b>, 10 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41523-020-0153-3" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41523-020-0153-3" aria-label="Article reference 57" data-doi="10.1038/s41523-020-0153-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXlslyrur4%3D" aria-label="CAS reference 57">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20development%20of%20immunotherapies%20for%20HER2%2B%20breast%20cancer%3A%20a%20review%20of%20HER2-directed%20monoclonal%20antibodies%20and%20beyond&amp;journal=NPJ%20Breast%20Cancer&amp;doi=10.1038%2Fs41523-020-0153-3&amp;volume=6&amp;publication_year=2020&amp;author=RLB%2CC&amp;author=BJ%2CC">
                    Google Scholar</a> 
                </p></li><li data-counter="58."><p id="ref-CR58">Piperno-Neumann, S. et al. Abstract CT002: phase 3 randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma. <i>Cancer Res.</i> <b>81</b>, CT002 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1538-7445.AM2021-CT002" data-track-action="article reference" href="https://doi.org/10.1158%2F1538-7445.AM2021-CT002" aria-label="Article reference 58" data-doi="10.1158/1538-7445.AM2021-CT002">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Abstract%20CT002%3A%20phase%203%20randomized%20trial%20comparing%20tebentafusp%20with%20investigator%E2%80%99s%20choice%20in%20first%20line%20metastatic%20uveal%20melanoma&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F1538-7445.AM2021-CT002&amp;volume=81&amp;publication_year=2021&amp;author=Piperno-Neumann%2CS">
                    Google Scholar</a> 
                </p></li><li data-counter="59."><p id="ref-CR59">Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. <i>Nat. Med.</i> <b>4</b>, 321–327 (1998).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nm0398-321" data-track-action="article reference" href="https://doi.org/10.1038%2Fnm0398-321" aria-label="Article reference 59" data-doi="10.1038/nm0398-321">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1cXhs1Kju7c%3D" aria-label="CAS reference 59">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9500606" aria-label="PubMed reference 59">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2064864" aria-label="PubMed Central reference 59">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunologic%20and%20therapeutic%20evaluation%20of%20a%20synthetic%20peptide%20vaccine%20for%20the%20treatment%20of%20patients%20with%20metastatic%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm0398-321&amp;volume=4&amp;pages=321-327&amp;publication_year=1998&amp;author=Rosenberg%2CSA">
                    Google Scholar</a> 
                </p></li><li data-counter="60."><p id="ref-CR60">Schwartzentruber, D. J. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. <i>N. Engl. J. Med.</i> <b>364</b>, 2119–2127 (2011).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1012863" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1012863" aria-label="Article reference 60" data-doi="10.1056/NEJMoa1012863">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXnt1Cmt7Y%3D" aria-label="CAS reference 60">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21631324" aria-label="PubMed reference 60">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517182" aria-label="PubMed Central reference 60">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=gp100%20peptide%20vaccine%20and%20interleukin-2%20in%20patients%20with%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1012863&amp;volume=364&amp;pages=2119-2127&amp;publication_year=2011&amp;author=Schwartzentruber%2CDJ">
                    Google Scholar</a> 
                </p></li><li data-counter="61."><p id="ref-CR61">Cunha, A. C., Weigle, B., Kiessling, A., Bachmann, M. &amp; Rieber, E. P. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. <i>Cancer Lett.</i> <b>236</b>, 229–238 (2006).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.canlet.2005.05.021" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.canlet.2005.05.021" aria-label="Article reference 61" data-doi="10.1016/j.canlet.2005.05.021">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28XkvVynu7k%3D" aria-label="CAS reference 61">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16046056" aria-label="PubMed reference 61">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 61" href="http://scholar.google.com/scholar_lookup?&amp;title=Tissue-specificity%20of%20prostate%20specific%20antigens%3A%20comparative%20analysis%20of%20transcript%20levels%20in%20prostate%20and%20non-prostatic%20tissues&amp;journal=Cancer%20Lett.&amp;doi=10.1016%2Fj.canlet.2005.05.021&amp;volume=236&amp;pages=229-238&amp;publication_year=2006&amp;author=Cunha%2CAC&amp;author=Weigle%2CB&amp;author=Kiessling%2CA&amp;author=Bachmann%2CM&amp;author=Rieber%2CEP">
                    Google Scholar</a> 
                </p></li><li data-counter="62."><p id="ref-CR62">McNeel, D. G. et al. Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer. <i>J. Clin. Oncol</i>. <b>37</b>, 3507–3517 (2019).</p></li><li data-counter="63."><p id="ref-CR63">Kim, P. et al. Adoptive T cell therapy targeting somatic p53 mutations. <i>J. Immunother. Cancer</i> <b>8</b>, A165–A166 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1136/jitc-2020-000980" data-track-action="article reference" href="https://doi.org/10.1136%2Fjitc-2020-000980" aria-label="Article reference 63" data-doi="10.1136/jitc-2020-000980">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 63" href="http://scholar.google.com/scholar_lookup?&amp;title=Adoptive%20T%20cell%20therapy%20targeting%20somatic%20p53%20mutations&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1136%2Fjitc-2020-000980&amp;volume=8&amp;pages=A165-A166&amp;publication_year=2020&amp;author=Kim%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="64."><p id="ref-CR64">Antonia, S. J. et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. <i>Clin. Cancer Res.</i> <b>12</b>, 878–887 (2006).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-05-2013" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-05-2013" aria-label="Article reference 64" data-doi="10.1158/1078-0432.CCR-05-2013">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28XhtFeiu7w%3D" aria-label="CAS reference 64">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16467102" aria-label="PubMed reference 64">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=Combination%20of%20p53%20cancer%20vaccine%20with%20chemotherapy%20in%20patients%20with%20extensive%20stage%20small%20cell%20lung%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-05-2013&amp;volume=12&amp;pages=878-887&amp;publication_year=2006&amp;author=Antonia%2CSJ">
                    Google Scholar</a> 
                </p></li><li data-counter="65."><p id="ref-CR65">Hardwick, N. R. et al. p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. <i>Clin. Cancer Res.</i> <b>24</b>, 1315–1325 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-17-2709" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-17-2709" aria-label="Article reference 65" data-doi="10.1158/1078-0432.CCR-17-2709">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXks1ylsr8%3D" aria-label="CAS reference 65">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29301826" aria-label="PubMed reference 65">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856606" aria-label="PubMed Central reference 65">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=p53-reactive%20T%20cells%20are%20associated%20with%20clinical%20benefit%20in%20patients%20with%20platinum-resistant%20epithelial%20ovarian%20cancer%20after%20treatment%20with%20a%20p53%20vaccine%20and%20gemcitabine%20chemotherapy&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-17-2709&amp;volume=24&amp;pages=1315-1325&amp;publication_year=2018&amp;author=Hardwick%2CNR">
                    Google Scholar</a> 
                </p></li><li data-counter="66."><p id="ref-CR66">Chiappori, A. A. et al. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a <i>TP53</i>-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. <i>Cancer Immunol. Immunother.</i> <b>68</b>, 517–527 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00262-018-2287-9" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00262-018-2287-9" aria-label="Article reference 66" data-doi="10.1007/s00262-018-2287-9">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXis1WhtLzJ" aria-label="CAS reference 66">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30591959" aria-label="PubMed reference 66">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized-controlled%20phase%20II%20trial%20of%20salvage%20chemotherapy%20after%20immunization%20with%20a%20TP53-transfected%20dendritic%20cell-based%20vaccine%20%28Ad.p53-DC%29%20in%20patients%20with%20recurrent%20small%20cell%20lung%20cancer&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-018-2287-9&amp;volume=68&amp;pages=517-527&amp;publication_year=2019&amp;author=Chiappori%2CAA">
                    Google Scholar</a> 
                </p></li><li data-counter="67."><p id="ref-CR67">Speetjens, F. M. et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. <i>Clin. Cancer Res.</i> <b>15</b>, 1086–1095 (2009).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-08-2227" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-08-2227" aria-label="Article reference 67" data-doi="10.1158/1078-0432.CCR-08-2227">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXht1Ons7w%3D" aria-label="CAS reference 67">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19188184" aria-label="PubMed reference 67">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=Induction%20of%20p53-specific%20immunity%20by%20a%20p53%20synthetic%20long%20peptide%20vaccine%20in%20patients%20treated%20for%20metastatic%20colorectal%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-08-2227&amp;volume=15&amp;pages=1086-1095&amp;publication_year=2009&amp;author=Speetjens%2CFM">
                    Google Scholar</a> 
                </p></li><li data-counter="68."><p id="ref-CR68">Chung, V. et al. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. <i>Clin. Transl. Oncol.</i> <b>21</b>, 363–372 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s12094-018-1932-2" data-track-action="article reference" href="https://doi.org/10.1007%2Fs12094-018-1932-2" aria-label="Article reference 68" data-doi="10.1007/s12094-018-1932-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFagu7zI" aria-label="CAS reference 68">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30094792" aria-label="PubMed reference 68">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 68" href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20safety%20and%20efficacy%20of%20p53MVA%20vaccine%20combined%20with%20pembrolizumab%20in%20patients%20with%20advanced%20solid%20cancers&amp;journal=Clin.%20Transl.%20Oncol.&amp;doi=10.1007%2Fs12094-018-1932-2&amp;volume=21&amp;pages=363-372&amp;publication_year=2019&amp;author=Chung%2CV">
                    Google Scholar</a> 
                </p></li><li data-counter="69."><p id="ref-CR69">Quandt, J. et al. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. <i>Oncoimmunology</i> <b>7</b>, e1500671 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/2162402X.2018.1500671" data-track-action="article reference" href="https://doi.org/10.1080%2F2162402X.2018.1500671" aria-label="Article reference 69" data-doi="10.1080/2162402X.2018.1500671">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30524892" aria-label="PubMed reference 69">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279329" aria-label="PubMed Central reference 69">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-peptide%20vaccination%20with%20driver%20gene%20mutations%20in%20p53%20and%20Kras%20induces%20cancer%20mutation-specific%20effector%20as%20well%20as%20regulatory%20T%20cell%20responses&amp;journal=Oncoimmunology&amp;doi=10.1080%2F2162402X.2018.1500671&amp;volume=7&amp;publication_year=2018&amp;author=Quandt%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="70."><p id="ref-CR70">Tang, K., Wu, Y. H., Song, Y. &amp; Yu, B. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. <i>J. Hematol. Oncol.</i> <b>14</b>, 68 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/s13045-021-01080-8" data-track-action="article reference" href="https://doi.org/10.1186%2Fs13045-021-01080-8" aria-label="Article reference 70" data-doi="10.1186/s13045-021-01080-8">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtFSksbzO" aria-label="CAS reference 70">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33883013" aria-label="PubMed reference 70">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061021" aria-label="PubMed Central reference 70">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 70" href="http://scholar.google.com/scholar_lookup?&amp;title=Indoleamine%202%2C3-dioxygenase%201%20%28IDO1%29%20inhibitors%20in%20clinical%20trials%20for%20cancer%20immunotherapy&amp;journal=J.%20Hematol.%20Oncol.&amp;doi=10.1186%2Fs13045-021-01080-8&amp;volume=14&amp;publication_year=2021&amp;author=Tang%2CK&amp;author=Wu%2CYH&amp;author=Song%2CY&amp;author=Yu%2CB">
                    Google Scholar</a> 
                </p></li><li data-counter="71."><p id="ref-CR71">Kjeldsen, J. W. et al. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nat. Med.</i> <b>27</b>, 2212–2223 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41591-021-01544-x" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-021-01544-x" aria-label="Article reference 71" data-doi="10.1038/s41591-021-01544-x">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXislWkt7zE" aria-label="CAS reference 71">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34887574" aria-label="PubMed reference 71">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904254" aria-label="PubMed Central reference 71">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 71" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%201%2F2%20trial%20of%20an%20immune-modulatory%20vaccine%20against%20IDO%2FPD-L1%20in%20combination%20with%20nivolumab%20in%20metastatic%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01544-x&amp;volume=27&amp;pages=2212-2223&amp;publication_year=2021&amp;author=Kjeldsen%2CJW">
                    Google Scholar</a> 
                </p></li><li data-counter="72."><p id="ref-CR72">Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature</i> <b>547</b>, 222–226 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nature23003" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature23003" aria-label="Article reference 72" data-doi="10.1038/nature23003">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFaqt73L" aria-label="CAS reference 72">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28678784" aria-label="PubMed reference 72">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 72" href="http://scholar.google.com/scholar_lookup?&amp;title=Personalized%20RNA%20mutanome%20vaccines%20mobilize%20poly-specific%20therapeutic%20immunity%20against%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature23003&amp;volume=547&amp;pages=222-226&amp;publication_year=2017&amp;author=Sahin%2CU">
                    Google Scholar</a> 
                </p></li><li data-counter="73."><p id="ref-CR73">Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. <i>Protein Sci.</i> <b>12</b>, 1007–1017 (2003).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1110/ps.0239403" data-track-action="article reference" href="https://doi.org/10.1110%2Fps.0239403" aria-label="Article reference 73" data-doi="10.1110/ps.0239403">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD3sXjtl2jtL8%3D" aria-label="CAS reference 73">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12717023" aria-label="PubMed reference 73">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323871" aria-label="PubMed Central reference 73">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 73" href="http://scholar.google.com/scholar_lookup?&amp;title=Reliable%20prediction%20of%20T-cell%20epitopes%20using%20neural%20networks%20with%20novel%20sequence%20representations&amp;journal=Protein%20Sci.&amp;doi=10.1110%2Fps.0239403&amp;volume=12&amp;pages=1007-1017&amp;publication_year=2003&amp;author=Nielsen%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="74."><p id="ref-CR74">Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> <b>547</b>, 217–221 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nature22991" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature22991" aria-label="Article reference 74" data-doi="10.1038/nature22991">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFaqt7rO" aria-label="CAS reference 74">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28678778" aria-label="PubMed reference 74">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577644" aria-label="PubMed Central reference 74">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 74" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20immunogenic%20personal%20neoantigen%20vaccine%20for%20patients%20with%20melanoma&amp;journal=Nature&amp;doi=10.1038%2Fnature22991&amp;volume=547&amp;pages=217-221&amp;publication_year=2017&amp;author=Ott%2CPA">
                    Google Scholar</a> 
                </p></li><li data-counter="75."><p id="ref-CR75">Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. <i>Cell</i> <b>183</b>, 347–362 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.cell.2020.08.053" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2020.08.053" aria-label="Article reference 75" data-doi="10.1016/j.cell.2020.08.053">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitF2jtLfJ" aria-label="CAS reference 75">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33064988" aria-label="PubMed reference 75">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 75" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20Ib%20trial%20of%20personalized%20neoantigen%20therapy%20plus%20anti-PD-1%20in%20patients%20with%20advanced%20melanoma%2C%20non-small%20cell%20lung%20cancer%2C%20or%20bladder%20cancer&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;volume=183&amp;pages=347-362&amp;publication_year=2020&amp;author=Ott%2CPA">
                    Google Scholar</a> 
                </p></li><li data-counter="76."><p id="ref-CR76">Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. <i>Science</i> <b>348</b>, 803–808 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/science.aaa3828" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aaa3828" aria-label="Article reference 76" data-doi="10.1126/science.aaa3828">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXotFahsLc%3D" aria-label="CAS reference 76">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25837513" aria-label="PubMed reference 76">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549796" aria-label="PubMed Central reference 76">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 76" href="http://scholar.google.com/scholar_lookup?&amp;title=Cancer%20immunotherapy.%20A%20dendritic%20cell%20vaccine%20increases%20the%20breadth%20and%20diversity%20of%20melanoma%20neoantigen-specific%20T%20cells&amp;journal=Science&amp;doi=10.1126%2Fscience.aaa3828&amp;volume=348&amp;pages=803-808&amp;publication_year=2015&amp;author=Carreno%2CBM">
                    Google Scholar</a> 
                </p></li><li data-counter="77."><p id="ref-CR77">Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> <b>565</b>, 234–239 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41586-018-0792-9" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-018-0792-9" aria-label="Article reference 77" data-doi="10.1038/s41586-018-0792-9">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisFyksLvE" aria-label="CAS reference 77">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30568305" aria-label="PubMed reference 77">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 77" href="http://scholar.google.com/scholar_lookup?&amp;title=Neoantigen%20vaccine%20generates%20intratumoral%20T%20cell%20responses%20in%20phase%20Ib%20glioblastoma%20trial&amp;journal=Nature&amp;doi=10.1038%2Fs41586-018-0792-9&amp;volume=565&amp;pages=234-239&amp;publication_year=2019&amp;author=Keskin%2CDB">
                    Google Scholar</a> 
                </p></li><li data-counter="78."><p id="ref-CR78">Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nat. Med.</i> <b>27</b>, 515–525 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41591-020-01206-4" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-020-01206-4" aria-label="Article reference 78" data-doi="10.1038/s41591-020-01206-4">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33479501" aria-label="PubMed reference 78">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273876" aria-label="PubMed Central reference 78">PubMed Central</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvFeiurg%3D" aria-label="CAS reference 78">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 78" href="http://scholar.google.com/scholar_lookup?&amp;title=Personal%20neoantigen%20vaccines%20induce%20persistent%20memory%20T%20cell%20responses%20and%20epitope%20spreading%20in%20patients%20with%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-020-01206-4&amp;volume=27&amp;publication_year=2021&amp;author=Hu%2CZ">
                    Google Scholar</a> 
                </p></li><li data-counter="79."><p id="ref-CR79">Cafri, G. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. <i>J. Clin. Invest.</i> <b>130</b>, 5976–5988 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1172/JCI134915" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI134915" aria-label="Article reference 79" data-doi="10.1172/JCI134915">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33016924" aria-label="PubMed reference 79">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598064" aria-label="PubMed Central reference 79">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 79" href="http://scholar.google.com/scholar_lookup?&amp;title=mRNA%20vaccine-induced%20neoantigen-specific%20T%20cell%20immunity%20in%20patients%20with%20gastrointestinal%20cancer&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI134915&amp;volume=130&amp;publication_year=2020&amp;author=Cafri%2CG">
                    Google Scholar</a> 
                </p></li><li data-counter="80."><p id="ref-CR80">Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> <b>565</b>, 240–245 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41586-018-0810-y" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-018-0810-y" aria-label="Article reference 80" data-doi="10.1038/s41586-018-0810-y">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisFyksLvN" aria-label="CAS reference 80">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30568303" aria-label="PubMed reference 80">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 80" href="http://scholar.google.com/scholar_lookup?&amp;title=Actively%20personalized%20vaccination%20trial%20for%20newly%20diagnosed%20glioblastoma&amp;journal=Nature&amp;doi=10.1038%2Fs41586-018-0810-y&amp;volume=565&amp;pages=240-245&amp;publication_year=2019&amp;author=Hilf%2CN">
                    Google Scholar</a> 
                </p></li><li data-counter="81."><p id="ref-CR81">Burger, M. L. et al. Antigen dominance hierarchies shape TCF1<sup>+</sup> progenitor CD8 T cell phenotypes in tumors. <i>Cell</i> <b>184</b>, 4996–5014 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.cell.2021.08.020" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2021.08.020" aria-label="Article reference 81" data-doi="10.1016/j.cell.2021.08.020">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitVGlsLrK" aria-label="CAS reference 81">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34534464" aria-label="PubMed reference 81">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 81" href="http://scholar.google.com/scholar_lookup?&amp;title=Antigen%20dominance%20hierarchies%20shape%20TCF1%2B%20progenitor%20CD8%20T%20cell%20phenotypes%20in%20tumors&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2021.08.020&amp;volume=184&amp;pages=4996-5014&amp;publication_year=2021&amp;author=Burger%2CML">
                    Google Scholar</a> 
                </p></li><li data-counter="82."><p id="ref-CR82">Drake, C. G. et al. Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: immunogenicity, safety, and efficacy results from two ongoing phase I studies. <i>J. Clin. Oncol.</i> <b>38</b>, 3137–3137 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2020.38.15_suppl.3137" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2020.38.15_suppl.3137" aria-label="Article reference 82" data-doi="10.1200/JCO.2020.38.15_suppl.3137">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 82" href="http://scholar.google.com/scholar_lookup?&amp;title=Personalized%20viral-based%20prime%2Fboost%20immunotherapy%20targeting%20patient-specific%20or%20shared%20neoantigens%3A%20immunogenicity%2C%20safety%2C%20and%20efficacy%20results%20from%20two%20ongoing%20phase%20I%20studies&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2020.38.15_suppl.3137&amp;volume=38&amp;pages=3137-3137&amp;publication_year=2020&amp;author=Drake%2CCG">
                    Google Scholar</a> 
                </p></li><li data-counter="83."><p id="ref-CR83">Marron, T. U., Ronner, L., Martin, P. E., Flowers, C. R. &amp; Brody, J. D. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. <i>Immunotherapy</i> <b>8</b>, 1335–1346 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.2217/imt-2016-0080" data-track-action="article reference" href="https://doi.org/10.2217%2Fimt-2016-0080" aria-label="Article reference 83" data-doi="10.2217/imt-2016-0080">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XitFams77J" aria-label="CAS reference 83">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27993085" aria-label="PubMed reference 83">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 83" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccine%20strategies%20for%20the%20treatment%20of%20lymphoma%3A%20preclinical%20progress%20and%20clinical%20trial%20update&amp;journal=Immunotherapy&amp;doi=10.2217%2Fimt-2016-0080&amp;volume=8&amp;pages=1335-1346&amp;publication_year=2016&amp;author=Marron%2CTU&amp;author=Ronner%2CL&amp;author=Martin%2CPE&amp;author=Flowers%2CCR&amp;author=Brody%2CJD">
                    Google Scholar</a> 
                </p></li><li data-counter="84."><p id="ref-CR84">KA, F. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. <i>N. Engl. J. Med.</i> <b>307</b>, 686–687 (1982).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJM198209093071118" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJM198209093071118" aria-label="Article reference 84" data-doi="10.1056/NEJM198209093071118">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 84" href="http://scholar.google.com/scholar_lookup?&amp;title=Treatment%20of%20B-cell%20lymphoma%20with%20monoclonal%20anti-idiotype%20antibody&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJM198209093071118&amp;volume=307&amp;pages=686-687&amp;publication_year=1982&amp;author=KA%2CF">
                    Google Scholar</a> 
                </p></li><li data-counter="85."><p id="ref-CR85">M, N. et al. Rat bone marrow-derived dendritic cells generated with GM-CSF/IL-4 or FLT3L exhibit distinct phenotypical and functional characteristics. <i>J. Leukoc. Biol.</i> <b>99</b>, 437–446 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1189/jlb.1AB0914-433RR" data-track-action="article reference" href="https://doi.org/10.1189%2Fjlb.1AB0914-433RR" aria-label="Article reference 85" data-doi="10.1189/jlb.1AB0914-433RR">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhsF2ksrrO" aria-label="CAS reference 85">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 85" href="http://scholar.google.com/scholar_lookup?&amp;title=Rat%20bone%20marrow-derived%20dendritic%20cells%20generated%20with%20GM-CSF%2FIL-4%20or%20FLT3L%20exhibit%20distinct%20phenotypical%20and%20functional%20characteristics&amp;journal=J.%20Leukoc.%20Biol.&amp;doi=10.1189%2Fjlb.1AB0914-433RR&amp;volume=99&amp;pages=437-446&amp;publication_year=2016&amp;author=M%2CN">
                    Google Scholar</a> 
                </p></li><li data-counter="86."><p id="ref-CR86">Delong, T. et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. <i>Science</i> <b>351</b>, 711–714 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/science.aad2791" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aad2791" aria-label="Article reference 86" data-doi="10.1126/science.aad2791">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xit1OjsLw%3D" aria-label="CAS reference 86">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26912858" aria-label="PubMed reference 86">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884646" aria-label="PubMed Central reference 86">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 86" href="http://scholar.google.com/scholar_lookup?&amp;title=Pathogenic%20CD4%20T%20cells%20in%20type%201%20diabetes%20recognize%20epitopes%20formed%20by%20peptide%20fusion&amp;journal=Science&amp;doi=10.1126%2Fscience.aad2791&amp;volume=351&amp;pages=711-714&amp;publication_year=2016&amp;author=Delong%2CT">
                    Google Scholar</a> 
                </p></li><li data-counter="87."><p id="ref-CR87">Peng, X. et al. A-to-I RNA editing contributes to proteomic diversity in cancer. <i>Cancer Cell</i> <b>33</b>, 817–828 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ccell.2018.03.026" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ccell.2018.03.026" aria-label="Article reference 87" data-doi="10.1016/j.ccell.2018.03.026">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXosFWhtLs%3D" aria-label="CAS reference 87">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29706454" aria-label="PubMed reference 87">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953833" aria-label="PubMed Central reference 87">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 87" href="http://scholar.google.com/scholar_lookup?&amp;title=A-to-I%20RNA%20editing%20contributes%20to%20proteomic%20diversity%20in%20cancer&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2018.03.026&amp;volume=33&amp;pages=817-828&amp;publication_year=2018&amp;author=Peng%2CX">
                    Google Scholar</a> 
                </p></li><li data-counter="88."><p id="ref-CR88">Moseley, P. Stress proteins and the immune response. <i>Immunopharmacology</i> <b>48</b>, 299–302 (2000).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0162-3109(00)00227-7" data-track-action="article reference" href="https://doi.org/10.1016%2FS0162-3109%2800%2900227-7" aria-label="Article reference 88" data-doi="10.1016/S0162-3109(00)00227-7">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD3cXlvV2nuro%3D" aria-label="CAS reference 88">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10960671" aria-label="PubMed reference 88">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 88" href="http://scholar.google.com/scholar_lookup?&amp;title=Stress%20proteins%20and%20the%20immune%20response&amp;journal=Immunopharmacology&amp;doi=10.1016%2FS0162-3109%2800%2900227-7&amp;volume=48&amp;pages=299-302&amp;publication_year=2000&amp;author=Moseley%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="89."><p id="ref-CR89">Testori, A. et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group. <i>J. Clin. Oncol.</i> <b>26</b>, 955–962 (2008).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2007.11.9941" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2007.11.9941" aria-label="Article reference 89" data-doi="10.1200/JCO.2007.11.9941">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXjtFelt7s%3D" aria-label="CAS reference 89">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18281670" aria-label="PubMed reference 89">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 89" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20III%20comparison%20of%20vitespen%2C%20an%20autologous%20tumor-derived%20heat%20shock%20protein%20gp96%20peptide%20complex%20vaccine%2C%20with%20physician%E2%80%99s%20choice%20of%20treatment%20for%20stage%20IV%20melanoma%3A%20the%20C-100-21%20Study%20Group&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2007.11.9941&amp;volume=26&amp;pages=955-962&amp;publication_year=2008&amp;author=Testori%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="90."><p id="ref-CR90">Wood, C. et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. <i>Lancet</i> <b>372</b>, 145–154 (2008).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(08)60697-2" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2808%2960697-2" aria-label="Article reference 90" data-doi="10.1016/S0140-6736(08)60697-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXosVynurY%3D" aria-label="CAS reference 90">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18602688" aria-label="PubMed reference 90">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 90" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20adjuvant%20autologous%20therapeutic%20vaccine%20%28HSPPC-96%3B%20vitespen%29%20versus%20observation%20alone%20for%20patients%20at%20high%20risk%20of%20recurrence%20after%20nephrectomy%20for%20renal%20cell%20carcinoma%3A%20a%20multicentre%2C%20open-label%2C%20randomised%20phase%20III%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2808%2960697-2&amp;volume=372&amp;pages=145-154&amp;publication_year=2008&amp;author=Wood%2CC">
                    Google Scholar</a> 
                </p></li><li data-counter="91."><p id="ref-CR91">Bloch, O. et al. Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. <i>Clin. Cancer Res.</i> <b>23</b>, 3575–3584 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-16-1369" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-16-1369" aria-label="Article reference 91" data-doi="10.1158/1078-0432.CCR-16-1369">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFKiu7%2FM" aria-label="CAS reference 91">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28193626" aria-label="PubMed reference 91">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511566" aria-label="PubMed Central reference 91">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 91" href="http://scholar.google.com/scholar_lookup?&amp;title=Autologous%20heat%20shock%20protein%20peptide%20vaccination%20for%20newly%20diagnosed%20glioblastoma%3A%20impact%20of%20peripheral%20PD-L1%20expression%20on%20response%20to%20therapy&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-1369&amp;volume=23&amp;pages=3575-3584&amp;publication_year=2017&amp;author=Bloch%2CO">
                    Google Scholar</a> 
                </p></li><li data-counter="92."><p id="ref-CR92">Kozłowska, A., Mackiewicz, J. &amp; Mackiewicz, A. Therapeutic gene modified cell based cancer vaccines. <i>Gene</i> <b>525</b>, 200–207 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.gene.2013.03.056" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.gene.2013.03.056" aria-label="Article reference 92" data-doi="10.1016/j.gene.2013.03.056">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23566846" aria-label="PubMed reference 92">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXmvVWgtr0%3D" aria-label="CAS reference 92">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 92" href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20gene%20modified%20cell%20based%20cancer%20vaccines&amp;journal=Gene&amp;doi=10.1016%2Fj.gene.2013.03.056&amp;volume=525&amp;pages=200-207&amp;publication_year=2013&amp;author=Koz%C5%82owska%2CA&amp;author=Mackiewicz%2CJ&amp;author=Mackiewicz%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="93."><p id="ref-CR93">Eager, R. &amp; Nemunaitis, J. GM-CSF gene-transduced tumor vaccines. <i>Mol. Ther.</i> <b>12</b>, 18–27 (2005).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ymthe.2005.02.012" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ymthe.2005.02.012" aria-label="Article reference 93" data-doi="10.1016/j.ymthe.2005.02.012">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXlt1Gls78%3D" aria-label="CAS reference 93">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15963916" aria-label="PubMed reference 93">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 93" href="http://scholar.google.com/scholar_lookup?&amp;title=GM-CSF%20gene-transduced%20tumor%20vaccines&amp;journal=Mol.%20Ther.&amp;doi=10.1016%2Fj.ymthe.2005.02.012&amp;volume=12&amp;pages=18-27&amp;publication_year=2005&amp;author=Eager%2CR&amp;author=Nemunaitis%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="94."><p id="ref-CR94">Ho, V. T. et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial. <i>Blood Adv.</i> <b>6</b>, 2183–2194 (2021).</p></li><li data-counter="95."><p id="ref-CR95">Ghisoli, M. et al. Three-year follow up of GMCSF/bi-shRNA<sup>furin</sup> DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing’s sarcoma. <i>Mol. Ther.</i> <b>24</b>, 1478–1483 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/mt.2016.86" data-track-action="article reference" href="https://doi.org/10.1038%2Fmt.2016.86" aria-label="Article reference 95" data-doi="10.1038/mt.2016.86">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhsVCgsLnO" aria-label="CAS reference 95">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27109631" aria-label="PubMed reference 95">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023386" aria-label="PubMed Central reference 95">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 95" href="http://scholar.google.com/scholar_lookup?&amp;title=Three-year%20follow%20up%20of%20GMCSF%2Fbi-shRNAfurin%20DNA-transfected%20autologous%20tumor%20immunotherapy%20%28Vigil%29%20in%20metastatic%20advanced%20Ewing%E2%80%99s%20sarcoma&amp;journal=Mol.%20Ther.&amp;doi=10.1038%2Fmt.2016.86&amp;volume=24&amp;pages=1478-1483&amp;publication_year=2016&amp;author=Ghisoli%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="96."><p id="ref-CR96">Rocconi, R. P. et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>Lancet Oncol.</i> <b>21</b>, 1661–1672 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(20)30533-7" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2820%2930533-7" aria-label="Article reference 96" data-doi="10.1016/S1470-2045(20)30533-7">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFCgsrrL" aria-label="CAS reference 96">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33271095" aria-label="PubMed reference 96">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 96" href="http://scholar.google.com/scholar_lookup?&amp;title=Gemogenovatucel-T%20%28Vigil%29%20immunotherapy%20as%20maintenance%20in%20frontline%20stage%20III%2FIV%20ovarian%20cancer%20%28VITAL%29%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%202b%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2820%2930533-7&amp;volume=21&amp;pages=1661-1672&amp;publication_year=2020&amp;author=Rocconi%2CRP">
                    Google Scholar</a> 
                </p></li><li data-counter="97."><p id="ref-CR97">Vermorken, J. B. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. <i>Lancet</i> <b>353</b>, 345–350 (1999).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(98)07186-4" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2898%2907186-4" aria-label="Article reference 97" data-doi="10.1016/S0140-6736(98)07186-4">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaK1M7jtl2gtQ%3D%3D" aria-label="CAS reference 97">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9950438" aria-label="PubMed reference 97">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 97" href="http://scholar.google.com/scholar_lookup?&amp;title=Active%20specific%20immunotherapy%20for%20stage%20II%20and%20stage%20III%20human%20colon%20cancer%3A%20a%20randomised%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2898%2907186-4&amp;volume=353&amp;pages=345-350&amp;publication_year=1999&amp;author=Vermorken%2CJB">
                    Google Scholar</a> 
                </p></li><li data-counter="98."><p id="ref-CR98">Prins, R. M. et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. <i>J. Immunother.</i> <b>36</b>, 152–157 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/CJI.0b013e3182811ae4" data-track-action="article reference" href="https://doi.org/10.1097%2FCJI.0b013e3182811ae4" aria-label="Article reference 98" data-doi="10.1097/CJI.0b013e3182811ae4">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXitlCis7c%3D" aria-label="CAS reference 98">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23377664" aria-label="PubMed reference 98">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568250" aria-label="PubMed Central reference 98">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 98" href="http://scholar.google.com/scholar_lookup?&amp;title=Comparison%20of%20glioma-associated%20antigen%20peptide-loaded%20versus%20autologous%20tumor%20lysate-loaded%20dendritic%20cell%20vaccination%20in%20malignant%20glioma%20patients&amp;journal=J.%20Immunother.&amp;doi=10.1097%2FCJI.0b013e3182811ae4&amp;volume=36&amp;pages=152-157&amp;publication_year=2013&amp;author=Prins%2CRM">
                    Google Scholar</a> 
                </p></li><li data-counter="99."><p id="ref-CR99">Dillman, R. O. et al. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. <i>J. Immunother. Cancer</i> <b>6</b>, 19 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/s40425-018-0330-1" data-track-action="article reference" href="https://doi.org/10.1186%2Fs40425-018-0330-1" aria-label="Article reference 99" data-doi="10.1186/s40425-018-0330-1">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29510745" aria-label="PubMed reference 99">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840808" aria-label="PubMed Central reference 99">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 99" href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20phase%20II%20trial%20of%20autologous%20dendritic%20cell%20vaccines%20versus%20autologous%20tumor%20cell%20vaccines%20in%20metastatic%20melanoma%3A%205-year%20follow%20up%20and%20additional%20analyses&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-018-0330-1&amp;volume=6&amp;publication_year=2018&amp;author=Dillman%2CRO">
                    Google Scholar</a> 
                </p></li><li data-counter="100."><p id="ref-CR100">Di Nicola, M. et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> <b>113</b>, 18–27 (2009).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood-2008-06-165654" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2008-06-165654" aria-label="Article reference 100" data-doi="10.1182/blood-2008-06-165654">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18809757" aria-label="PubMed reference 100">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXmtFSksA%3D%3D" aria-label="CAS reference 100">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 100" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccination%20with%20autologous%20tumor-loaded%20dendritic%20cells%20induces%20clinical%20and%20immunologic%20responses%20in%20indolent%20B-cell%20lymphoma%20patients%20with%20relapsed%20and%20measurable%20disease%3A%20a%20pilot%20study&amp;journal=Blood&amp;doi=10.1182%2Fblood-2008-06-165654&amp;volume=113&amp;pages=18-27&amp;publication_year=2009&amp;author=Nicola%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="101."><p id="ref-CR101">Tanyi, J. L. et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. <i>Sci. Transl. Med.</i> <b>10</b>, eaao5931 (2018).</p></li><li data-counter="102."><p id="ref-CR102">Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. <i>Nat. Rev. Immunol.</i> <b>20</b>, 7–24 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41577-019-0210-z" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41577-019-0210-z" aria-label="Article reference 102" data-doi="10.1038/s41577-019-0210-z">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1yls7jE" aria-label="CAS reference 102">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31467405" aria-label="PubMed reference 102">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 102" href="http://scholar.google.com/scholar_lookup?&amp;title=Dendritic%20cells%20in%20cancer%20immunology%20and%20immunotherapy&amp;journal=Nat.%20Rev.%20Immunol.&amp;doi=10.1038%2Fs41577-019-0210-z&amp;volume=20&amp;pages=7-24&amp;publication_year=2020&amp;author=Wculek%2CSK">
                    Google Scholar</a> 
                </p></li><li data-counter="103."><p id="ref-CR103">Subbiah, V. et al. Cytokines produced by dendritic cells administered intratumorally correlate with clinical outcome in patients with diverse cancers. <i>Clin. Cancer Res.</i> <b>24</b>, 3845–3856 (2018).</p></li><li data-counter="104."><p id="ref-CR104">Kolstad, A. et al. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> <b>125</b>, 82–89 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood-2014-07-592162" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2014-07-592162" aria-label="Article reference 104" data-doi="10.1182/blood-2014-07-592162">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXmtFOjtw%3D%3D" aria-label="CAS reference 104">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25293773" aria-label="PubMed reference 104">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 104" href="http://scholar.google.com/scholar_lookup?&amp;title=Sequential%20intranodal%20immunotherapy%20induces%20antitumor%20immunity%20and%20correlated%20regression%20of%20disseminated%20follicular%20lymphoma&amp;journal=Blood&amp;doi=10.1182%2Fblood-2014-07-592162&amp;volume=125&amp;pages=82-89&amp;publication_year=2015&amp;author=Kolstad%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="105."><p id="ref-CR105">Cox, M. C. et al. Clinical and antitumor immune responses in relapsed/refractory follicular lymphoma patients after intranodal injections of IFNα-dendritic cells and rituximab: a phase I clinical trial. <i>Clin. Cancer Res.</i> <b>25</b>, 5231–5272 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-19-0709" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-19-0709" aria-label="Article reference 105" data-doi="10.1158/1078-0432.CCR-19-0709">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXltVegtLY%3D" aria-label="CAS reference 105">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31171545" aria-label="PubMed reference 105">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 105" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20and%20antitumor%20immune%20responses%20in%20relapsed%2Frefractory%20follicular%20lymphoma%20patients%20after%20intranodal%20injections%20of%20IFN%CE%B1-dendritic%20cells%20and%20rituximab%3A%20a%20phase%20I%20clinical%20trial&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-0709&amp;volume=25&amp;pages=5231-5272&amp;publication_year=2019&amp;author=Cox%2CMC">
                    Google Scholar</a> 
                </p></li><li data-counter="106."><p id="ref-CR106">Lee, J. M. et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8<sup>+</sup> T-cell infiltration. <i>Clin. Cancer Res.</i> <b>23</b>, 4556–4568 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-16-2821" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-16-2821" aria-label="Article reference 106" data-doi="10.1158/1078-0432.CCR-16-2821">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlCmu7vL" aria-label="CAS reference 106">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28468947" aria-label="PubMed reference 106">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599263" aria-label="PubMed Central reference 106">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 106" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20trial%20of%20intratumoral%20injection%20of%20CCL21%20gene-modified%20dendritic%20cells%20in%20lung%20cancer%20elicits%20tumor-specific%20immune%20responses%20and%20CD8%2B%20T-cell%20infiltration&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-2821&amp;volume=23&amp;pages=4556-4568&amp;publication_year=2017&amp;author=Lee%2CJM">
                    Google Scholar</a> 
                </p></li><li data-counter="107."><p id="ref-CR107">Lowenstein, P. R. et al. First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: initial results from the therapeutic reprogramming of the brain immune system. <i>J. Clin. Oncol.</i> <b>37</b>, 2019 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2019.37.15_suppl.2019" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2019.37.15_suppl.2019" aria-label="Article reference 107" data-doi="10.1200/JCO.2019.37.15_suppl.2019">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 107" href="http://scholar.google.com/scholar_lookup?&amp;title=First-in-human%20phase%20I%20trial%20of%20the%20combination%20of%20two%20adenoviral%20vectors%20expressing%20HSV1-TK%20and%20FLT3L%20for%20the%20treatment%20of%20newly%20diagnosed%20resectable%20malignant%20glioma%3A%20initial%20results%20from%20the%20therapeutic%20reprogramming%20of%20the%20brain%20immune%20system&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2019.37.15_suppl.2019&amp;volume=37&amp;publication_year=2019&amp;author=Lowenstein%2CPR">
                    Google Scholar</a> 
                </p></li><li data-counter="108."><p id="ref-CR108">Papagno, L. et al. The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8<sup>+</sup> T-cell responses in vitro. <i>Sci. Rep.</i> <b>10</b>, 11620 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41598-020-67704-0" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41598-020-67704-0" aria-label="Article reference 108" data-doi="10.1038/s41598-020-67704-0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVWhsb7N" aria-label="CAS reference 108">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32669577" aria-label="PubMed reference 108">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363897" aria-label="PubMed Central reference 108">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 108" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20TLR9%20ligand%20CpG%20ODN%202006%20is%20a%20poor%20adjuvant%20for%20the%20induction%20of%20de%20novo%20CD8%2B%20T-cell%20responses%20in%20vitro&amp;journal=Sci.%20Rep.&amp;doi=10.1038%2Fs41598-020-67704-0&amp;volume=10&amp;publication_year=2020&amp;author=Papagno%2CL">
                    Google Scholar</a> 
                </p></li><li data-counter="109."><p id="ref-CR109">Haymaker, C. et al. Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. <i>Cancer Discov.</i> <b>11</b>, 1996–2013 (2021).</p></li><li data-counter="110."><p id="ref-CR110">Milhem, M. et al. Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. <i>J. Immunother. Cancer</i> <b>8</b>, A331 (2020).</p><p><a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 110" href="http://scholar.google.com/scholar_lookup?&amp;title=Intratumoral%20injection%20of%20CMP-001%2C%20a%20Toll-like%20receptor%209%20%28TLR9%29%20agonist%2C%20in%20combination%20with%20pembrolizumab%20reversed%20programmed%20death%20receptor%201%20%28PD-1%29%20blockade%20resistance%20in%20advanced%20melanoma&amp;journal=J.%20Immunother.%20Cancer&amp;volume=8&amp;publication_year=2020&amp;author=Milhem%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="111."><p id="ref-CR111">Ribas, A. et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. <i>Cancer Discov.</i> <b>8</b>, 1250–1257 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-18-0280" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-18-0280" aria-label="Article reference 111" data-doi="10.1158/2159-8290.CD-18-0280">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXmt1ehtLc%3D" aria-label="CAS reference 111">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30154193" aria-label="PubMed reference 111">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719557" aria-label="PubMed Central reference 111">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 111" href="http://scholar.google.com/scholar_lookup?&amp;title=SD-101%20in%20combination%20with%20pembrolizumab%20in%20advanced%20melanoma%3A%20results%20of%20a%20phase%20Ib%2C%20multicenter%20study&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-18-0280&amp;volume=8&amp;pages=1250-1257&amp;publication_year=2018&amp;author=Ribas%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="112."><p id="ref-CR112">Frank, M. J. et al. In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. <i>Cancer Discov.</i> <b>8</b>, 1258–1269 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-18-0743" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-18-0743" aria-label="Article reference 112" data-doi="10.1158/2159-8290.CD-18-0743">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXmt1ehsbs%3D" aria-label="CAS reference 112">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30154192" aria-label="PubMed reference 112">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171524" aria-label="PubMed Central reference 112">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 112" href="http://scholar.google.com/scholar_lookup?&amp;title=In%20situ%20vaccination%20with%20a%20TLR9%20agonist%20and%20local%20low-dose%20radiation%20induces%20systemic%20responses%20in%20untreated%20indolent%20lymphoma&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-18-0743&amp;volume=8&amp;pages=1258-1269&amp;publication_year=2018&amp;author=Frank%2CMJ">
                    Google Scholar</a> 
                </p></li><li data-counter="113."><p id="ref-CR113">Sultan, H., Salazar, A. M. &amp; Celis, E. Poly-ICLC, a multi-functional immune modulator for treating cancer. <i>Semin. Immunol.</i> <b>49</b>, 101414 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.smim.2020.101414" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.smim.2020.101414" aria-label="Article reference 113" data-doi="10.1016/j.smim.2020.101414">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvFyis7fP" aria-label="CAS reference 113">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33011064" aria-label="PubMed reference 113">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 113" href="http://scholar.google.com/scholar_lookup?&amp;title=Poly-ICLC%2C%20a%20multi-functional%20immune%20modulator%20for%20treating%20cancer&amp;journal=Semin.%20Immunol.&amp;doi=10.1016%2Fj.smim.2020.101414&amp;volume=49&amp;publication_year=2020&amp;author=Sultan%2CH&amp;author=Salazar%2CAM&amp;author=Celis%2CE">
                    Google Scholar</a> 
                </p></li><li data-counter="114."><p id="ref-CR114">de la Torre, A. N. et al. A phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. <i>J. Hepatocell. Carcinoma</i> <b>4</b>, 111–121 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.2147/JHC.S136652" data-track-action="article reference" href="https://doi.org/10.2147%2FJHC.S136652" aria-label="Article reference 114" data-doi="10.2147/JHC.S136652">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28848723" aria-label="PubMed reference 114">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557908" aria-label="PubMed Central reference 114">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 114" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20I%20trial%20using%20local%20regional%20treatment%2C%20nonlethal%20irradiation%2C%20intratumoral%20and%20systemic%20polyinosinic-polycytidylic%20acid%20polylysine%20carboxymethylcellulose%20to%20treat%20liver%20cancer%3A%20in%20search%20of%20the%20abscopal%20effect&amp;journal=J.%20Hepatocell.%20Carcinoma&amp;doi=10.2147%2FJHC.S136652&amp;volume=4&amp;pages=111-121&amp;publication_year=2017&amp;author=Torre%2CAN">
                    Google Scholar</a> 
                </p></li><li data-counter="115."><p id="ref-CR115">Kyi, C. et al. Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial. <i>Clin. Cancer Res</i>. <b>24</b>, 4937–4948 (2018).</p></li><li data-counter="116."><p id="ref-CR116">Rodríguez-Ruiz, M. E. et al. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. <i>Ann. Oncol.</i> <b>29</b>, 1312–1319 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/annonc/mdy089" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdy089" aria-label="Article reference 116" data-doi="10.1093/annonc/mdy089">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29554212" aria-label="PubMed reference 116">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 116" href="http://scholar.google.com/scholar_lookup?&amp;title=Combined%20immunotherapy%20encompassing%20intratumoral%20poly-ICLC%2C%20dendritic-cell%20vaccination%20and%20radiotherapy%20in%20advanced%20cancer%20patients&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdy089&amp;volume=29&amp;pages=1312-1319&amp;publication_year=2018&amp;author=Rodr%C3%ADguez-Ruiz%2CME">
                    Google Scholar</a> 
                </p></li><li data-counter="117."><p id="ref-CR117">Theodoraki, M. N. et al. Helicase-driven activation of NFκB–COX2 pathway mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment. <i>Cancer Res.</i> <b>78</b>, 4292–4302 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-17-3985" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-17-3985" aria-label="Article reference 117" data-doi="10.1158/0008-5472.CAN-17-3985">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVWrsb3O" aria-label="CAS reference 117">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29853604" aria-label="PubMed reference 117">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636317" aria-label="PubMed Central reference 117">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 117" href="http://scholar.google.com/scholar_lookup?&amp;title=Helicase-driven%20activation%20of%20NF%CE%BAB%E2%80%93COX2%20pathway%20mediates%20the%20immunosuppressive%20component%20of%20dsRNA-driven%20inflammation%20in%20the%20human%20tumor%20microenvironment&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-17-3985&amp;volume=78&amp;pages=4292-4302&amp;publication_year=2018&amp;author=Theodoraki%2CMN">
                    Google Scholar</a> 
                </p></li><li data-counter="118."><p id="ref-CR118">Márquez-Rodas, I. et al. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors. <i>Sci. Transl. Med.</i> <b>12</b>, eabb0391 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.abb0391" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.abb0391" aria-label="Article reference 118" data-doi="10.1126/scitranslmed.abb0391">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33055241" aria-label="PubMed reference 118">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitV2hs7%2FE" aria-label="CAS reference 118">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 118" href="http://scholar.google.com/scholar_lookup?&amp;title=Intratumoral%20nanoplexed%20poly%20I%3AC%20BO-112%20in%20combination%20with%20systemic%20anti-PD-1%20for%20patients%20with%20anti-PD-1-refractory%20tumors&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.abb0391&amp;volume=12&amp;publication_year=2020&amp;author=M%C3%A1rquez-Rodas%2CI">
                    Google Scholar</a> 
                </p></li><li data-counter="119."><p id="ref-CR119">Kobayashi, G. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432]. <i>Nihon Geka Gakkai Zasshi</i> <b>91</b>, 68–76 (1990).</p></li><li data-counter="120."><p id="ref-CR120">Endo, H. et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. <i>J. Hepatobiliary Pancreat. Sci.</i> <b>19</b>, 465–475 (2012).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00534-011-0457-7" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00534-011-0457-7" aria-label="Article reference 120" data-doi="10.1007/s00534-011-0457-7">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21983893" aria-label="PubMed reference 120">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 120" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20trial%20of%20preoperative%20intratumoral%20injection%20of%20immature%20dendritic%20cells%20and%20OK-432%20for%20resectable%20pancreatic%20cancer%20patients&amp;journal=J.%20Hepatobiliary%20Pancreat.%20Sci.&amp;doi=10.1007%2Fs00534-011-0457-7&amp;volume=19&amp;pages=465-475&amp;publication_year=2012&amp;author=Endo%2CH">
                    Google Scholar</a> 
                </p></li><li data-counter="121."><p id="ref-CR121">Bhatia, S. et al. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with Merkel cell carcinoma. <i>Clin. Cancer Res.</i> <b>25</b>, 1185–1195 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-18-0469" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-18-0469" aria-label="Article reference 121" data-doi="10.1158/1078-0432.CCR-18-0469">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtlOmt7rO" aria-label="CAS reference 121">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30093453" aria-label="PubMed reference 121">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 121" href="http://scholar.google.com/scholar_lookup?&amp;title=Intratumoral%20G100%2C%20a%20TLR4%20agonist%2C%20induces%20antitumor%20immune%20responses%20and%20tumor%20regression%20in%20patients%20with%20Merkel%20cell%20carcinoma&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-0469&amp;volume=25&amp;pages=1185-1195&amp;publication_year=2019&amp;author=Bhatia%2CS">
                    Google Scholar</a> 
                </p></li><li data-counter="122."><p id="ref-CR122">Flowers, C. R. et al. Long term follow-up of a phase 2 study examining intratumoral G100 alone and in combination with pembrolizumab in patients with follicular lymphoma. <i>Blood</i> <b>132</b>, 2892 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood-2018-99-117932" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2018-99-117932" aria-label="Article reference 122" data-doi="10.1182/blood-2018-99-117932">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 122" href="http://scholar.google.com/scholar_lookup?&amp;title=Long%20term%20follow-up%20of%20a%20phase%202%20study%20examining%20intratumoral%20G100%20alone%20and%20in%20combination%20with%20pembrolizumab%20in%20patients%20with%20follicular%20lymphoma&amp;journal=Blood&amp;doi=10.1182%2Fblood-2018-99-117932&amp;volume=132&amp;publication_year=2018&amp;author=Flowers%2CCR">
                    Google Scholar</a> 
                </p></li><li data-counter="123."><p id="ref-CR123">Melero, I., Castanon, E., Alvarez, M., Champiat, S. &amp; Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. <i>Nat. Rev. Clin. Oncol.</i> <b>18</b>, 558–576 (2021).</p></li><li data-counter="124."><p id="ref-CR124">Alvarez, M. et al. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. <i>J. Immunother. Cancer</i> <b>9</b>, e002953 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1136/jitc-2021-002953" data-track-action="article reference" href="https://doi.org/10.1136%2Fjitc-2021-002953" aria-label="Article reference 124" data-doi="10.1136/jitc-2021-002953">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34824158" aria-label="PubMed reference 124">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627419" aria-label="PubMed Central reference 124">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 124" href="http://scholar.google.com/scholar_lookup?&amp;title=Intratumoral%20co-injection%20of%20the%20poly%20I%3AC-derivative%20BO-112%20and%20a%20STING%20agonist%20synergize%20to%20achieve%20local%20and%20distant%20anti-tumor%20efficacy&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1136%2Fjitc-2021-002953&amp;volume=9&amp;publication_year=2021&amp;author=Alvarez%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="125."><p id="ref-CR125">Andtbacka, R. H. I. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. <i>J. Clin. Oncol.</i> <b>33</b>, 2780–2788 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2014.58.3377" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2014.58.3377" aria-label="Article reference 125" data-doi="10.1200/JCO.2014.58.3377">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XkvFWisL4%3D" aria-label="CAS reference 125">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26014293" aria-label="PubMed reference 125">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 125" href="http://scholar.google.com/scholar_lookup?&amp;title=Talimogene%20laherparepvec%20improves%20durable%20response%20rate%20in%20patients%20with%20advanced%20melanoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2014.58.3377&amp;volume=33&amp;pages=2780-2788&amp;publication_year=2015&amp;author=Andtbacka%2CRHI">
                    Google Scholar</a> 
                </p></li><li data-counter="126."><p id="ref-CR126">Kaufman, H. L. et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. <i>J. Immunother. Cancer</i> <b>4</b>, 12 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/s40425-016-0116-2" data-track-action="article reference" href="https://doi.org/10.1186%2Fs40425-016-0116-2" aria-label="Article reference 126" data-doi="10.1186/s40425-016-0116-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26981242" aria-label="PubMed reference 126">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791835" aria-label="PubMed Central reference 126">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 126" href="http://scholar.google.com/scholar_lookup?&amp;title=Systemic%20versus%20local%20responses%20in%20melanoma%20patients%20treated%20with%20talimogene%20laherparepvec%20from%20a%20multi-institutional%20phase%20II%20study&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-016-0116-2&amp;volume=4&amp;publication_year=2016&amp;author=Kaufman%2CHL">
                    Google Scholar</a> 
                </p></li><li data-counter="127."><p id="ref-CR127">Noguera-Ortega, E., Guallar-Garrido, S. &amp; Julián, E. Mycobacteria-based vaccines as immunotherapy for non-urological cancers. <i>Cancers</i> <b>12</b>, 1802 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3390/cancers12071802" data-track-action="article reference" href="https://doi.org/10.3390%2Fcancers12071802" aria-label="Article reference 127" data-doi="10.3390/cancers12071802">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFKgtL%2FJ" aria-label="CAS reference 127">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408281" aria-label="PubMed Central reference 127">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 127" href="http://scholar.google.com/scholar_lookup?&amp;title=Mycobacteria-based%20vaccines%20as%20immunotherapy%20for%20non-urological%20cancers&amp;journal=Cancers&amp;doi=10.3390%2Fcancers12071802&amp;volume=12&amp;publication_year=2020&amp;author=Noguera-Ortega%2CE&amp;author=Guallar-Garrido%2CS&amp;author=Juli%C3%A1n%2CE">
                    Google Scholar</a> 
                </p></li><li data-counter="128."><p id="ref-CR128">Janku, F. et al. Phase I clinical study of intratumoral injection of oncolytic <i>Clostridium novyi</i>-NT spores in patients with advanced cancers. <i>Eur. J. Cancer</i> <b>69</b>, S94 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0959-8049(16)32878-7" data-track-action="article reference" href="https://doi.org/10.1016%2FS0959-8049%2816%2932878-7" aria-label="Article reference 128" data-doi="10.1016/S0959-8049(16)32878-7">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 128" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20clinical%20study%20of%20intratumoral%20injection%20of%20oncolytic%20Clostridium%20novyi-NT%20spores%20in%20patients%20with%20advanced%20cancers&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2FS0959-8049%2816%2932878-7&amp;volume=69&amp;publication_year=2016&amp;author=Janku%2CF">
                    Google Scholar</a> 
                </p></li><li data-counter="129."><p id="ref-CR129">Hammerich, L., Bhardwaj, N., Kohrt, H. E. &amp; Brody, J. D. In situ vaccination for the treatment of cancer. <i>Immunotherapy</i> <b>8</b>, 315–330 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.2217/imt.15.120" data-track-action="article reference" href="https://doi.org/10.2217%2Fimt.15.120" aria-label="Article reference 129" data-doi="10.2217/imt.15.120">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XjtFyjsrs%3D" aria-label="CAS reference 129">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26860335" aria-label="PubMed reference 129">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 129" href="http://scholar.google.com/scholar_lookup?&amp;title=In%20situ%20vaccination%20for%20the%20treatment%20of%20cancer&amp;journal=Immunotherapy&amp;doi=10.2217%2Fimt.15.120&amp;volume=8&amp;pages=315-330&amp;publication_year=2016&amp;author=Hammerich%2CL&amp;author=Bhardwaj%2CN&amp;author=Kohrt%2CHE&amp;author=Brody%2CJD">
                    Google Scholar</a> 
                </p></li><li data-counter="130."><p id="ref-CR130">O’Donnell, J. S., Teng, M. W. L. &amp; Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nat. Rev. Clin. Oncol.</i> <b>16</b>, 151–167 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41571-018-0142-8" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41571-018-0142-8" aria-label="Article reference 130" data-doi="10.1038/s41571-018-0142-8">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVemur7J" aria-label="CAS reference 130">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 130" href="http://scholar.google.com/scholar_lookup?&amp;title=Cancer%20immunoediting%20and%20resistance%20to%20T%20cell-based%20immunotherapy&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-018-0142-8&amp;volume=16&amp;pages=151-167&amp;publication_year=2018&amp;author=O%E2%80%99Donnell%2CJS&amp;author=Teng%2CMWL&amp;author=Smyth%2CMJ">
                    Google Scholar</a> 
                </p></li><li data-counter="131."><p id="ref-CR131">Morris, Z. S. et al. Tumor-specific inhibition of in situ vaccination by distant untreated tumor sites. <i>Cancer Immunol. Res.</i> <b>6</b>, 825–834 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-17-0353" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-17-0353" aria-label="Article reference 131" data-doi="10.1158/2326-6066.CIR-17-0353">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXht1alu7%2FO" aria-label="CAS reference 131">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29748391" aria-label="PubMed reference 131">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030484" aria-label="PubMed Central reference 131">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 131" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor-specific%20inhibition%20of%20in%20situ%20vaccination%20by%20distant%20untreated%20tumor%20sites&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-17-0353&amp;volume=6&amp;pages=825-834&amp;publication_year=2018&amp;author=Morris%2CZS">
                    Google Scholar</a> 
                </p></li><li data-counter="132."><p id="ref-CR132">Dannull, J. et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. <i>J. Clin. Invest.</i> <b>115</b>, 3623–3633 (2005).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1172/JCI25947" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI25947" aria-label="Article reference 132" data-doi="10.1172/JCI25947">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtlSqtLjJ" aria-label="CAS reference 132">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16308572" aria-label="PubMed reference 132">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288834" aria-label="PubMed Central reference 132">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 132" href="http://scholar.google.com/scholar_lookup?&amp;title=Enhancement%20of%20vaccine-mediated%20antitumor%20immunity%20in%20cancer%20patients%20after%20depletion%20of%20regulatory%20T%20cells&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI25947&amp;volume=115&amp;pages=3623-3633&amp;publication_year=2005&amp;author=Dannull%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="133."><p id="ref-CR133">Marabelle, A. et al. Depleting tumor-specific T<sub>regs</sub> at a single site eradicates disseminated tumors. <i>J. Clin. Invest.</i> <b>123</b>, 2447–2463 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1172/JCI64859" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI64859" aria-label="Article reference 133" data-doi="10.1172/JCI64859">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXpsFWksbc%3D" aria-label="CAS reference 133">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23728179" aria-label="PubMed reference 133">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668834" aria-label="PubMed Central reference 133">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 133" href="http://scholar.google.com/scholar_lookup?&amp;title=Depleting%20tumor-specific%20Tregs%20at%20a%20single%20site%20eradicates%20disseminated%20tumors&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI64859&amp;volume=123&amp;pages=2447-2463&amp;publication_year=2013&amp;author=Marabelle%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="134."><p id="ref-CR134">Kohrt, H. E. et al. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. <i>J. Immunother. Cancer</i> <b>4</b>, 15 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/s40425-016-0118-0" data-track-action="article reference" href="https://doi.org/10.1186%2Fs40425-016-0118-0" aria-label="Article reference 134" data-doi="10.1186/s40425-016-0118-0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26981245" aria-label="PubMed reference 134">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791805" aria-label="PubMed Central reference 134">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 134" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunodynamics%3A%20a%20cancer%20immunotherapy%20trials%20network%20review%20of%20immune%20monitoring%20in%20immuno-oncology%20clinical%20trials&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-016-0118-0&amp;volume=4&amp;publication_year=2016&amp;author=Kohrt%2CHE">
                    Google Scholar</a> 
                </p></li><li data-counter="135."><p id="ref-CR135">Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. <i>Int. Immunol.</i> <b>8</b>, 765–772 (1996).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/intimm/8.5.765" data-track-action="article reference" href="https://doi.org/10.1093%2Fintimm%2F8.5.765" aria-label="Article reference 135" data-doi="10.1093/intimm/8.5.765">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK28Xjt1Kmurw%3D" aria-label="CAS reference 135">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8671665" aria-label="PubMed reference 135">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 135" href="http://scholar.google.com/scholar_lookup?&amp;title=Expression%20of%20the%20PD-1%20antigen%20on%20the%20surface%20of%20stimulated%20mouse%20T%20and%20B%20lymphocytes&amp;journal=Int.%20Immunol.&amp;doi=10.1093%2Fintimm%2F8.5.765&amp;volume=8&amp;pages=765-772&amp;publication_year=1996&amp;author=Agata%2CY">
                    Google Scholar</a> 
                </p></li><li data-counter="136."><p id="ref-CR136">Gros, A. et al. PD-1 identifies the patient-specific CD8<sup>+</sup> tumor-reactive repertoire infiltrating human tumors. <i>J. Clin. Invest.</i> <b>124</b>, 2246–2259 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1172/JCI73639" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI73639" aria-label="Article reference 136" data-doi="10.1172/JCI73639">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXotVSntrY%3D" aria-label="CAS reference 136">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24667641" aria-label="PubMed reference 136">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001555" aria-label="PubMed Central reference 136">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 136" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-1%20identifies%20the%20patient-specific%20CD8%2B%20tumor-reactive%20repertoire%20infiltrating%20human%20tumors&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI73639&amp;volume=124&amp;pages=2246-2259&amp;publication_year=2014&amp;author=Gros%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="137."><p id="ref-CR137">Neelapu, S. S. et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. <i>Nat. Med.</i> <b>11</b>, 986–991 (2005).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nm1290" data-track-action="article reference" href="https://doi.org/10.1038%2Fnm1290" aria-label="Article reference 137" data-doi="10.1038/nm1290">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXpslelurg%3D" aria-label="CAS reference 137">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16116429" aria-label="PubMed reference 137">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 137" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccine-induced%20tumor-specific%20immunity%20despite%20severe%20B-cell%20depletion%20in%20mantle%20cell%20lymphoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm1290&amp;volume=11&amp;pages=986-991&amp;publication_year=2005&amp;author=Neelapu%2CSS">
                    Google Scholar</a> 
                </p></li><li data-counter="138."><p id="ref-CR138">Di Giacomo, A. M. et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncol.</i> <b>13</b>, 879–886 (2012).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(12)70324-8" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2812%2970324-8" aria-label="Article reference 138" data-doi="10.1016/S1470-2045(12)70324-8">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22894884" aria-label="PubMed reference 138">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xhtlait7zI" aria-label="CAS reference 138">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 138" href="http://scholar.google.com/scholar_lookup?&amp;title=Ipilimumab%20and%20fotemustine%20in%20patients%20with%20advanced%20melanoma%20%28NIBIT-M1%29%3A%20an%20open-label%2C%20single-arm%20phase%202%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2812%2970324-8&amp;volume=13&amp;pages=879-886&amp;publication_year=2012&amp;author=Giacomo%2CAM">
                    Google Scholar</a> 
                </p></li><li data-counter="139."><p id="ref-CR139">Robins, H. S. et al. Digital genomic quantification of tumor-infiltrating lymphocytes. <i>Sci. Transl. Med.</i> <b>5</b>, 214ra169 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.3007247" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.3007247" aria-label="Article reference 139" data-doi="10.1126/scitranslmed.3007247">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24307693" aria-label="PubMed reference 139">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026017" aria-label="PubMed Central reference 139">PubMed Central</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXmsVyms7k%3D" aria-label="CAS reference 139">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 139" href="http://scholar.google.com/scholar_lookup?&amp;title=Digital%20genomic%20quantification%20of%20tumor-infiltrating%20lymphocytes&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.3007247&amp;volume=5&amp;publication_year=2013&amp;author=Robins%2CHS">
                    Google Scholar</a> 
                </p></li><li data-counter="140."><p id="ref-CR140">Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> <b>515</b>, 568–571 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nature13954" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature13954" aria-label="Article reference 140" data-doi="10.1038/nature13954">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFanu7jL" aria-label="CAS reference 140">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25428505" aria-label="PubMed reference 140">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418" aria-label="PubMed Central reference 140">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 140" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-1%20blockade%20induces%20responses%20by%20inhibiting%20adaptive%20immune%20resistance&amp;journal=Nature&amp;doi=10.1038%2Fnature13954&amp;volume=515&amp;pages=568-571&amp;publication_year=2014&amp;author=Tumeh%2CPC">
                    Google Scholar</a> 
                </p></li><li data-counter="141."><p id="ref-CR141">Tickotsky, N., Sagiv, T., Prilusky, J., Shifrut, E. &amp; Friedman, N. McPAS-TCR: a manually-curated catalogue of pathology-associated T cell receptor sequences. <i>Bioinformatics</i> <b>33</b>, 2924–2929 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/bioinformatics/btx286" data-track-action="article reference" href="https://doi.org/10.1093%2Fbioinformatics%2Fbtx286" aria-label="Article reference 141" data-doi="10.1093/bioinformatics/btx286">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvFenu7%2FI" aria-label="CAS reference 141">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28481982" aria-label="PubMed reference 141">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 141" href="http://scholar.google.com/scholar_lookup?&amp;title=McPAS-TCR%3A%20a%20manually-curated%20catalogue%20of%20pathology-associated%20T%20cell%20receptor%20sequences&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbtx286&amp;volume=33&amp;pages=2924-2929&amp;publication_year=2017&amp;author=Tickotsky%2CN&amp;author=Sagiv%2CT&amp;author=Prilusky%2CJ&amp;author=Shifrut%2CE&amp;author=Friedman%2CN">
                    Google Scholar</a> 
                </p></li><li data-counter="142."><p id="ref-CR142">Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8<sup>+</sup> T cells in melanoma. <i>Nature</i> <b>596</b>, 119–125 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41586-021-03704-y" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-021-03704-y" aria-label="Article reference 142" data-doi="10.1038/s41586-021-03704-y">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhs1Skt7%2FJ" aria-label="CAS reference 142">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34290406" aria-label="PubMed reference 142">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187974" aria-label="PubMed Central reference 142">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 142" href="http://scholar.google.com/scholar_lookup?&amp;title=Phenotype%2C%20specificity%20and%20avidity%20of%20antitumour%20CD8%2B%20T%20cells%20in%20melanoma&amp;journal=Nature&amp;doi=10.1038%2Fs41586-021-03704-y&amp;volume=596&amp;pages=119-125&amp;publication_year=2021&amp;author=Oliveira%2CG">
                    Google Scholar</a> 
                </p></li><li data-counter="143."><p id="ref-CR143">Welters, M. J. P. et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. <i>Proc. Natl Acad. Sci. USA</i> <b>107</b>, 11895–11899 (2010).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1073/pnas.1006500107" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.1006500107" aria-label="Article reference 143" data-doi="10.1073/pnas.1006500107">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXovVart7c%3D" aria-label="CAS reference 143">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20547850" aria-label="PubMed reference 143">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900675" aria-label="PubMed Central reference 143">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 143" href="http://scholar.google.com/scholar_lookup?&amp;title=Success%20or%20failure%20of%20vaccination%20for%20HPV16-positive%20vulvar%20lesions%20correlates%20with%20kinetics%20and%20phenotype%20of%20induced%20T-cell%20responses&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1006500107&amp;volume=107&amp;pages=11895-11899&amp;publication_year=2010&amp;author=Welters%2CMJP">
                    Google Scholar</a> 
                </p></li><li data-counter="144."><p id="ref-CR144">Kirkwood, J. M. et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine ± granulocyte–monocyte colony-stimulating factor and/or IFIN-α2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. <i>Clin. Cancer Res.</i> <b>15</b>, 1443–1451 (2009).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-08-1231" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-08-1231" aria-label="Article reference 144" data-doi="10.1158/1078-0432.CCR-08-1231">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXitVOktL0%3D" aria-label="CAS reference 144">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19228745" aria-label="PubMed reference 144">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759898" aria-label="PubMed Central reference 144">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 144" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunogenicity%20and%20antitumor%20effects%20of%20vaccination%20with%20peptide%20vaccine%20%C2%B1%20granulocyte%E2%80%93monocyte%20colony-stimulating%20factor%20and%2For%20IFIN-%CE%B12b%20in%20advanced%20metastatic%20melanoma%3A%20Eastern%20Cooperative%20Oncology%20Group%20Phase%20II%20Trial%20E1696&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-08-1231&amp;volume=15&amp;pages=1443-1451&amp;publication_year=2009&amp;author=Kirkwood%2CJM">
                    Google Scholar</a> 
                </p></li><li data-counter="145."><p id="ref-CR145">Van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. <i>J. Clin. Oncol.</i> <b>31</b>, e439–e442 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2012.47.7521" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2012.47.7521" aria-label="Article reference 145" data-doi="10.1200/JCO.2012.47.7521">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24043743" aria-label="PubMed reference 145">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 145" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20exome%20analysis%20reveals%20neoantigen-specific%20T-cell%20reactivity%20in%20an%20ipilimumab-responsive%20melanoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2012.47.7521&amp;volume=31&amp;pages=e439-e442&amp;publication_year=2013&amp;author=Rooij%2CN">
                    Google Scholar</a> 
                </p></li><li data-counter="146."><p id="ref-CR146">Mellman, I. et al. De-risking immunotherapy: report of a consensus workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunol. Res.</i> <b>4</b>, 279–288 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-16-0045" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-16-0045" aria-label="Article reference 146" data-doi="10.1158/2326-6066.CIR-16-0045">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xls1Grt70%3D" aria-label="CAS reference 146">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27036972" aria-label="PubMed reference 146">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 146" href="http://scholar.google.com/scholar_lookup?&amp;title=De-risking%20immunotherapy%3A%20report%20of%20a%20consensus%20workshop%20of%20the%20Cancer%20Immunotherapy%20Consortium%20of%20the%20Cancer%20Research%20Institute&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-16-0045&amp;volume=4&amp;pages=279-288&amp;publication_year=2016&amp;author=Mellman%2CI">
                    Google Scholar</a> 
                </p></li><li data-counter="147."><p id="ref-CR147">Danilova, L. et al. The Mutation-Associated Neoantigen Functional Expansion of Specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. <i>Cancer Immunol. Res.</i> <b>6</b>, 888–899 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-18-0129" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-18-0129" aria-label="Article reference 147" data-doi="10.1158/2326-6066.CIR-18-0129">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVWrsbbI" aria-label="CAS reference 147">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29895573" aria-label="PubMed reference 147">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072595" aria-label="PubMed Central reference 147">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 147" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Mutation-Associated%20Neoantigen%20Functional%20Expansion%20of%20Specific%20T%20cells%20%28MANAFEST%29%20assay%3A%20a%20sensitive%20platform%20for%20monitoring%20antitumor%20immunity&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-18-0129&amp;volume=6&amp;pages=888-899&amp;publication_year=2018&amp;author=Danilova%2CL">
                    Google Scholar</a> 
                </p></li><li data-counter="148."><p id="ref-CR148">Odunsi, K. et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. <i>Proc. Natl Acad. Sci. USA</i> <b>104</b>, 12837–12842 (2007).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1073/pnas.0703342104" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.0703342104" aria-label="Article reference 148" data-doi="10.1073/pnas.0703342104">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXptVejtLo%3D" aria-label="CAS reference 148">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17652518" aria-label="PubMed reference 148">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1937553" aria-label="PubMed Central reference 148">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 148" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccination%20with%20an%20NY-ESO-1%20peptide%20of%20HLA%20class%20I%2FII%20specificities%20induces%20integrated%20humoral%20and%20T%20cell%20responses%20in%20ovarian%20cancer&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0703342104&amp;volume=104&amp;pages=12837-12842&amp;publication_year=2007&amp;author=Odunsi%2CK">
                    Google Scholar</a> 
                </p></li><li data-counter="149."><p id="ref-CR149">Gasser, O. et al. A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. <i>Cancer Immunol. Immunother.</i> <b>67</b>, 285–298 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00262-017-2085-9" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00262-017-2085-9" aria-label="Article reference 149" data-doi="10.1007/s00262-017-2085-9">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslCmurrM" aria-label="CAS reference 149">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29094183" aria-label="PubMed reference 149">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 149" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20I%20vaccination%20study%20with%20dendritic%20cells%20loaded%20with%20NY-ESO-1%20and%20%CE%B1-galactosylceramide%3A%20induction%20of%20polyfunctional%20T%20cells%20in%20high-risk%20melanoma%20patients&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-017-2085-9&amp;volume=67&amp;pages=285-298&amp;publication_year=2018&amp;author=Gasser%2CO">
                    Google Scholar</a> 
                </p></li><li data-counter="150."><p id="ref-CR150">Clifton, G. T. T. et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer. <i>Clin. Cancer Res.</i> <b>26</b>, 2515–2523 (2020).</p></li><li data-counter="151."><p id="ref-CR151">Lesterhuis, W. J. et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. <i>Cancer Immunol. Immunother.</i> <b>60</b>, 249–260 (2011).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00262-010-0942-x" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00262-010-0942-x" aria-label="Article reference 151" data-doi="10.1007/s00262-010-0942-x">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXptFeqsQ%3D%3D" aria-label="CAS reference 151">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21069321" aria-label="PubMed reference 151">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 151" href="http://scholar.google.com/scholar_lookup?&amp;title=Wild-type%20and%20modified%20gp100%20peptide-pulsed%20dendritic%20cell%20vaccination%20of%20advanced%20melanoma%20patients%20can%20lead%20to%20long-term%20clinical%20responses%20independent%20of%20the%20peptide%20used&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-010-0942-x&amp;volume=60&amp;pages=249-260&amp;publication_year=2011&amp;author=Lesterhuis%2CWJ">
                    Google Scholar</a> 
                </p></li><li data-counter="152."><p id="ref-CR152">Steele, J. C. et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. <i>Gene Ther.</i> <b>18</b>, 584–593 (2011).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/gt.2011.1" data-track-action="article reference" href="https://doi.org/10.1038%2Fgt.2011.1" aria-label="Article reference 152" data-doi="10.1038/gt.2011.1">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhs12nsbo%3D" aria-label="CAS reference 152">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21307889" aria-label="PubMed reference 152">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 152" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%2FII%20trial%20of%20a%20dendritic%20cell%20vaccine%20transfected%20with%20DNA%20encoding%20melan%20A%20and%20gp100%20for%20patients%20with%20metastatic%20melanoma&amp;journal=Gene%20Ther.&amp;doi=10.1038%2Fgt.2011.1&amp;volume=18&amp;pages=584-593&amp;publication_year=2011&amp;author=Steele%2CJC">
                    Google Scholar</a> 
                </p></li><li data-counter="153."><p id="ref-CR153">Twardowski, P. et al. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. <i>Cancer Treat. Res. Commun.</i> <b>19</b>, 100116 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ctarc.2018.100116" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ctarc.2018.100116" aria-label="Article reference 153" data-doi="10.1016/j.ctarc.2018.100116">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30682445" aria-label="PubMed reference 153">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 153" href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20phase%20II%20trial%20of%20sipuleucel-T%20immunotherapy%20preceded%20by%20sensitizing%20radiation%20therapy%20and%20sipuleucel-T%20alone%20in%20patients%20with%20metastatic%20castrate%20resistant%20prostate%20cancer&amp;journal=Cancer%20Treat.%20Res.%20Commun.&amp;doi=10.1016%2Fj.ctarc.2018.100116&amp;volume=19&amp;publication_year=2019&amp;author=Twardowski%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="154."><p id="ref-CR154">McNeel, D. G. et al. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. <i>Clin. Cancer Res.</i> <b>20</b>, 3692–3704 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-14-0169" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-14-0169" aria-label="Article reference 154" data-doi="10.1158/1078-0432.CCR-14-0169">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtFKlsr7P" aria-label="CAS reference 154">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24850844" aria-label="PubMed reference 154">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102643" aria-label="PubMed Central reference 154">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 154" href="http://scholar.google.com/scholar_lookup?&amp;title=Real-time%20immune%20monitoring%20to%20guide%20plasmid%20DNA%20vaccination%20schedule%20targeting%20prostatic%20acid%20phosphatase%20in%20patients%20with%20castration-resistant%20prostate%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-14-0169&amp;volume=20&amp;pages=3692-3704&amp;publication_year=2014&amp;author=McNeel%2CDG">
                    Google Scholar</a> 
                </p></li><li data-counter="155."><p id="ref-CR155">Chung, V. M. et al. A phase 1 study of p53MVA vaccine in combination with pembrolizumab. <i>J. Clin. Oncol.</i> <b>36</b>, 206 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2018.36.5_suppl.206" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2018.36.5_suppl.206" aria-label="Article reference 155" data-doi="10.1200/JCO.2018.36.5_suppl.206">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 155" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%201%20study%20of%20p53MVA%20vaccine%20in%20combination%20with%20pembrolizumab&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2018.36.5_suppl.206&amp;volume=36&amp;publication_year=2018&amp;author=Chung%2CVM">
                    Google Scholar</a> 
                </p></li><li data-counter="156."><p id="ref-CR156">Freedman, A. et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte–macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. <i>J. Clin. Oncol.</i> <b>27</b>, 3036–3043 (2009).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2008.19.8903" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2008.19.8903" aria-label="Article reference 156" data-doi="10.1200/JCO.2008.19.8903">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXoslyisbo%3D" aria-label="CAS reference 156">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19414675" aria-label="PubMed reference 156">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646306" aria-label="PubMed Central reference 156">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 156" href="http://scholar.google.com/scholar_lookup?&amp;title=Placebo-controlled%20phase%20III%20trial%20of%20patient-specific%20immunotherapy%20with%20mitumprotimut-T%20and%20granulocyte%E2%80%93macrophage%20colony-stimulating%20factor%20after%20rituximab%20in%20patients%20with%20follicular%20lymphoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2008.19.8903&amp;volume=27&amp;pages=3036-3043&amp;publication_year=2009&amp;author=Freedman%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="157."><p id="ref-CR157">Levy, R. et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. <i>J. Clin. Oncol.</i> <b>32</b>, 1797–1803 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2012.43.9273" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2012.43.9273" aria-label="Article reference 157" data-doi="10.1200/JCO.2012.43.9273">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXht1ansLfL" aria-label="CAS reference 157">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24799467" aria-label="PubMed reference 157">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039868" aria-label="PubMed Central reference 157">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 157" href="http://scholar.google.com/scholar_lookup?&amp;title=Active%20idiotypic%20vaccination%20versus%20control%20immunotherapy%20for%20follicular%20lymphoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2012.43.9273&amp;volume=32&amp;pages=1797-1803&amp;publication_year=2014&amp;author=Levy%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="158."><p id="ref-CR158">Schuster, S. J. et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. <i>J. Clin. Oncol.</i> <b>29</b>, 2787–2794 (2011).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2010.33.3005" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2010.33.3005" aria-label="Article reference 158" data-doi="10.1200/JCO.2010.33.3005">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtVOnur%2FJ" aria-label="CAS reference 158">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21632504" aria-label="PubMed reference 158">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139394" aria-label="PubMed Central reference 158">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 158" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccination%20with%20patient-specific%20tumor-derived%20antigen%20in%20first%20remission%20improves%20disease-free%20survival%20in%20follicular%20lymphoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2010.33.3005&amp;volume=29&amp;pages=2787-2794&amp;publication_year=2011&amp;author=Schuster%2CSJ">
                    Google Scholar</a> 
                </p></li><li data-counter="159."><p id="ref-CR159">Hurvitz, S. A. &amp; Timmerman, J. M. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId™. <i>Expert Opin. Biol. Ther.</i> <b>5</b>, 841–852 (2005).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1517/14712598.5.6.841" data-track-action="article reference" href="https://doi.org/10.1517%2F14712598.5.6.841" aria-label="Article reference 159" data-doi="10.1517/14712598.5.6.841">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXkvV2nt7Y%3D" aria-label="CAS reference 159">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15952914" aria-label="PubMed reference 159">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 159" href="http://scholar.google.com/scholar_lookup?&amp;title=Recombinant%2C%20tumour-derived%20idiotype%20vaccination%20for%20indolent%20B%20cell%20non-Hodgkin%E2%80%99s%20lymphomas%3A%20a%20focus%20on%20FavId%E2%84%A2&amp;journal=Expert%20Opin.%20Biol.%20Ther.&amp;doi=10.1517%2F14712598.5.6.841&amp;volume=5&amp;pages=841-852&amp;publication_year=2005&amp;author=Hurvitz%2CSA&amp;author=Timmerman%2CJM">
                    Google Scholar</a> 
                </p></li><li data-counter="160."><p id="ref-CR160">Bloch, O. et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. <i>Neuro Oncol.</i> <b>16</b>, 274–279 (2014).</p></li><li data-counter="161."><p id="ref-CR161">Le, D. T. et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). <i>Clin. Cancer Res.</i> <b>25</b>, 5493–5502 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-18-2992" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-18-2992" aria-label="Article reference 161" data-doi="10.1158/1078-0432.CCR-18-2992">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXlvF2rtrk%3D" aria-label="CAS reference 161">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31126960" aria-label="PubMed reference 161">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376746" aria-label="PubMed Central reference 161">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 161" href="http://scholar.google.com/scholar_lookup?&amp;title=Results%20from%20a%20phase%20IIb%2C%20randomized%2C%20multicenter%20study%20of%20GVAX%20pancreas%20and%20CRS-207%20compared%20with%20chemotherapy%20in%20adults%20with%20previously%20treated%20metastatic%20pancreatic%20adenocarcinoma%20%28ECLIPSE%20study%29&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-2992&amp;volume=25&amp;pages=5493-5502&amp;publication_year=2019&amp;author=Le%2CDT">
                    Google Scholar</a> 
                </p></li><li data-counter="162."><p id="ref-CR162">Lee, V. et al. Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC). <i>J. Clin. Oncol.</i> <b>35</b>, TPS4154 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2017.35.15_suppl.TPS4154" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2017.35.15_suppl.TPS4154" aria-label="Article reference 162" data-doi="10.1200/JCO.2017.35.15_suppl.TPS4154">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 162" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20II%20study%20of%20GM-CSF%20secreting%20allogeneic%20pancreatic%20cancer%20vaccine%20%28GVAX%29%20with%20PD-1%20blockade%20antibody%20and%20stereotactic%20body%20radiation%20therapy%20%28SBRT%29%20for%20locally%20advanced%20pancreas%20cancer%20%28LAPC%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2017.35.15_suppl.TPS4154&amp;volume=35&amp;publication_year=2017&amp;author=Lee%2CV">
                    Google Scholar</a> 
                </p></li><li data-counter="163."><p id="ref-CR163">Carson, W. E. et al. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. <i>Cancer Immunol. Res.</i> <b>2</b>, 981–987 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-14-0052" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-14-0052" aria-label="Article reference 163" data-doi="10.1158/2326-6066.CIR-14-0052">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhslajsrrL" aria-label="CAS reference 163">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24994597" aria-label="PubMed reference 163">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185232" aria-label="PubMed Central reference 163">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 163" href="http://scholar.google.com/scholar_lookup?&amp;title=Adjuvant%20vaccine%20immunotherapy%20of%20resected%2C%20clinically%20node-negative%20melanoma%3A%20long-term%20outcome%20and%20impact%20of%20HLA%20class%20I%20antigen%20expression%20on%20overall%20survival&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-14-0052&amp;volume=2&amp;pages=981-987&amp;publication_year=2014&amp;author=Carson%2CWE">
                    Google Scholar</a> 
                </p></li><li data-counter="164."><p id="ref-CR164">Oh, J. et al. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. <i>Gynecol. Oncol.</i> <b>143</b>, 504–510 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ygyno.2016.09.018" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ygyno.2016.09.018" aria-label="Article reference 164" data-doi="10.1016/j.ygyno.2016.09.018">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhsFKjt73I" aria-label="CAS reference 164">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27678295" aria-label="PubMed reference 164">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 164" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20II%20study%20of%20Vigil%C2%AE%20DNA%20engineered%20immunotherapy%20as%20maintenance%20in%20advanced%20stage%20ovarian%20cancer&amp;journal=Gynecol.%20Oncol.&amp;doi=10.1016%2Fj.ygyno.2016.09.018&amp;volume=143&amp;pages=504-510&amp;publication_year=2016&amp;author=Oh%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="165."><p id="ref-CR165">Manning, L. et al. Assessment of low dose Vigil® engineered autologous tumor cell (EATC) immunotherapy in patients with advanced solid tumors. <i>Clin. Oncol.</i> <b>2</b>, 1254 (2017).</p></li><li data-counter="166."><p id="ref-CR166">Liau, L. M. et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>J. Transl. Med.</i> <b>16</b>, 142 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/s12967-018-1507-6" data-track-action="article reference" href="https://doi.org/10.1186%2Fs12967-018-1507-6" aria-label="Article reference 166" data-doi="10.1186/s12967-018-1507-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtFKms7jJ" aria-label="CAS reference 166">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29843811" aria-label="PubMed reference 166">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975654" aria-label="PubMed Central reference 166">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 166" href="http://scholar.google.com/scholar_lookup?&amp;title=First%20results%20on%20survival%20from%20a%20large%20phase%203%20clinical%20trial%20of%20an%20autologous%20dendritic%20cell%20vaccine%20in%20newly%20diagnosed%20glioblastoma&amp;journal=J.%20Transl.%20Med.&amp;doi=10.1186%2Fs12967-018-1507-6&amp;volume=16&amp;publication_year=2018&amp;author=Liau%2CLM">
                    Google Scholar</a> 
                </p></li><li data-counter="167."><p id="ref-CR167">Andtbacka, R. H. I. et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte–macrophage colony-stimulating factor in unresectable stage III–IV melanoma. <i>J. Immunother. Cancer</i> <b>7</b>, 145 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1186/s40425-019-0623-z" data-track-action="article reference" href="https://doi.org/10.1186%2Fs40425-019-0623-z" aria-label="Article reference 167" data-doi="10.1186/s40425-019-0623-z">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31171039" aria-label="PubMed reference 167">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554874" aria-label="PubMed Central reference 167">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 167" href="http://scholar.google.com/scholar_lookup?&amp;title=Final%20analyses%20of%20OPTiM%3A%20a%20randomized%20phase%20III%20trial%20of%20talimogene%20laherparepvec%20versus%20granulocyte%E2%80%93macrophage%20colony-stimulating%20factor%20in%20unresectable%20stage%20III%E2%80%93IV%20melanoma&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-019-0623-z&amp;volume=7&amp;publication_year=2019&amp;author=Andtbacka%2CRHI">
                    Google Scholar</a> 
                </p></li><li data-counter="168."><p id="ref-CR168">Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. <i>J. Clin. Oncol.</i> <b>36</b>, 1658–1667 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2017.73.7379" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2017.73.7379" aria-label="Article reference 168" data-doi="10.1200/JCO.2017.73.7379">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvV2iur4%3D" aria-label="CAS reference 168">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28981385" aria-label="PubMed reference 168">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 168" href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%2C%20open-label%20phase%20II%20study%20evaluating%20the%20efficacy%20and%20safety%20of%20talimogene%20laherparepvec%20in%20combination%20with%20ipilimumab%20versus%20ipilimumab%20alone%20in%20patients%20with%20advanced%2C%20unresectable%20melanoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2017.73.7379&amp;volume=36&amp;pages=1658-1667&amp;publication_year=2018&amp;author=Chesney%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="169."><p id="ref-CR169">Moehler, M. et al. Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE). <i>Oncoimmunology</i> <b>8</b>, 1615817 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/2162402X.2019.1615817" data-track-action="article reference" href="https://doi.org/10.1080%2F2162402X.2019.1615817" aria-label="Article reference 169" data-doi="10.1080/2162402X.2019.1615817">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3MvotFSqsA%3D%3D" aria-label="CAS reference 169">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31413923" aria-label="PubMed reference 169">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682346" aria-label="PubMed Central reference 169">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 169" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccinia-based%20oncolytic%20immunotherapy%20pexastimogene%20devacirepvec%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20after%20sorafenib%20failure%3A%20a%20randomized%20multicenter%20phase%20IIb%20trial%20%28TRAVERSE%29&amp;journal=Oncoimmunology&amp;doi=10.1080%2F2162402X.2019.1615817&amp;volume=8&amp;publication_year=2019&amp;author=Moehler%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="170."><p id="ref-CR170">Lang, F. F. et al. Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. <i>J. Clin. Oncol.</i> <b>36</b>, 1419–1427 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2017.75.8219" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2017.75.8219" aria-label="Article reference 170" data-doi="10.1200/JCO.2017.75.8219">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlCisbk%3D" aria-label="CAS reference 170">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29432077" aria-label="PubMed reference 170">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075856" aria-label="PubMed Central reference 170">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 170" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20DNX-2401%20%28delta-24-RGD%29%20oncolytic%20adenovirus%3A%20replication%20and%20immunotherapeutic%20effects%20in%20recurrent%20malignant%20glioma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2017.75.8219&amp;volume=36&amp;pages=1419-1427&amp;publication_year=2018&amp;author=Lang%2CFF">
                    Google Scholar</a> 
                </p></li><li data-counter="171."><p id="ref-CR171">Pascual-Pasto, G. et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. <i>Sci. Transl. Med.</i> <b>11</b>, eaat9321 (2019).</p></li><li data-counter="172."><p id="ref-CR172">Geletneky, K. et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. <i>Mol. Ther.</i> <b>25</b>, 2620–2634 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ymthe.2017.08.016" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ymthe.2017.08.016" aria-label="Article reference 172" data-doi="10.1016/j.ymthe.2017.08.016">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvFemur7N" aria-label="CAS reference 172">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28967558" aria-label="PubMed reference 172">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768665" aria-label="PubMed Central reference 172">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 172" href="http://scholar.google.com/scholar_lookup?&amp;title=Oncolytic%20H-1%20parvovirus%20shows%20safety%20and%20signs%20of%20immunogenic%20activity%20in%20a%20first%20phase%20I%2FIIa%20glioblastoma%20trial&amp;journal=Mol.%20Ther.&amp;doi=10.1016%2Fj.ymthe.2017.08.016&amp;volume=25&amp;pages=2620-2634&amp;publication_year=2017&amp;author=Geletneky%2CK">
                    Google Scholar</a> 
                </p></li><li data-counter="173."><p id="ref-CR173">Annels, N. E. et al. Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. <i>Clin. Cancer Res.</i> <b>25</b>, 5818–5831 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-18-4022" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-18-4022" aria-label="Article reference 173" data-doi="10.1158/1078-0432.CCR-18-4022">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsVKmsrw%3D" aria-label="CAS reference 173">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31273010" aria-label="PubMed reference 173">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 173" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20trial%20of%20an%20ICAM-1-targeted%20immunotherapeutic-coxsackievirus%20A21%20%28CVA21%29%20as%20an%20oncolytic%20agent%20against%20non%20muscle-invasive%20bladder%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-4022&amp;volume=25&amp;pages=5818-5831&amp;publication_year=2019&amp;author=Annels%2CNE">
                    Google Scholar</a> 
                </p></li><li data-counter="174."><p id="ref-CR174">Kicielinski, K. P. et al. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. <i>Mol. Ther.</i> <b>22</b>, 1056–1062 (2014).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/mt.2014.21" data-track-action="article reference" href="https://doi.org/10.1038%2Fmt.2014.21" aria-label="Article reference 174" data-doi="10.1038/mt.2014.21">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXksVSgt70%3D" aria-label="CAS reference 174">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24553100" aria-label="PubMed reference 174">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015229" aria-label="PubMed Central reference 174">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 174" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%201%20clinical%20trial%20of%20intratumoral%20reovirus%20infusion%20for%20the%20treatment%20of%20recurrent%20malignant%20gliomas%20in%20adults&amp;journal=Mol.%20Ther.&amp;doi=10.1038%2Fmt.2014.21&amp;volume=22&amp;pages=1056-1062&amp;publication_year=2014&amp;author=Kicielinski%2CKP">
                    Google Scholar</a> 
                </p></li><li data-counter="175."><p id="ref-CR175">Harrington, K. J. et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. <i>Clin. Cancer Res.</i> <b>16</b>, 3067–3077 (2010).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-10-0054" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-10-0054" aria-label="Article reference 175" data-doi="10.1158/1078-0432.CCR-10-0054">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXms1OjsLc%3D" aria-label="CAS reference 175">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20484020" aria-label="PubMed reference 175">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907942" aria-label="PubMed Central reference 175">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 175" href="http://scholar.google.com/scholar_lookup?&amp;title=Two-stage%20phase%20I%20dose-escalation%20study%20of%20intratumoral%20reovirus%20type%203%20dearing%20and%20palliative%20radiotherapy%20in%20patients%20with%20advanced%20cancers&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-10-0054&amp;volume=16&amp;pages=3067-3077&amp;publication_year=2010&amp;author=Harrington%2CKJ">
                    Google Scholar</a> 
                </p></li><li data-counter="176."><p id="ref-CR176">Ohri, N. et al. FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer. <i>J. Clin. Oncol.</i> <b>38</b>, 9618 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2020.38.15_suppl.9618" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2020.38.15_suppl.9618" aria-label="Article reference 176" data-doi="10.1200/JCO.2020.38.15_suppl.9618">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 176" href="http://scholar.google.com/scholar_lookup?&amp;title=FLT3%20ligand%20%28CDX-301%29%20and%20stereotactic%20radiotherapy%20for%20advanced%20non-small%20cell%20lung%20cancer&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2020.38.15_suppl.9618&amp;volume=38&amp;publication_year=2020&amp;author=Ohri%2CN">
                    Google Scholar</a> 
                </p></li><li data-counter="177."><p id="ref-CR177">Nemunaitis, J. et al. Pilot trial of genetically modified, attenuated <i>Salmonella</i> expressing the <i>E. coli</i> cytosine deaminase gene in refractory cancer patients. <i>Cancer Gene Ther.</i> <b>10</b>, 737–744 (2003).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/sj.cgt.7700634" data-track-action="article reference" href="https://doi.org/10.1038%2Fsj.cgt.7700634" aria-label="Article reference 177" data-doi="10.1038/sj.cgt.7700634">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD3sXnsVWmu70%3D" aria-label="CAS reference 177">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14502226" aria-label="PubMed reference 177">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 177" href="http://scholar.google.com/scholar_lookup?&amp;title=Pilot%20trial%20of%20genetically%20modified%2C%20attenuated%20Salmonella%20expressing%20the%20E.%20coli%20cytosine%20deaminase%20gene%20in%20refractory%20cancer%20patients&amp;journal=Cancer%20Gene%20Ther.&amp;doi=10.1038%2Fsj.cgt.7700634&amp;volume=10&amp;pages=737-744&amp;publication_year=2003&amp;author=Nemunaitis%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="178."><p id="ref-CR178">Drake, C. G. et al. Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted <i>Listeria monocytogenes</i>-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC). <i>J. Clin. Oncol.</i> <b>37</b>, e16509 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1200/JCO.2019.37.15_suppl.e16509" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2019.37.15_suppl.e16509" aria-label="Article reference 178" data-doi="10.1200/JCO.2019.37.15_suppl.e16509">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 178" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20preliminary%20immunogenicity%20of%20JNJ-64041809%2C%20a%20live%20attenuated%2C%20double-deleted%20Listeria%20monocytogenes-based%20immunotherapy%2C%20in%20metastatic%20castration-resistant%20prostate%20cancer%20%28mCRPC%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2019.37.15_suppl.e16509&amp;volume=37&amp;publication_year=2019&amp;author=Drake%2CCG">
                    Google Scholar</a> 
                </p></li><li data-counter="179."><p id="ref-CR179">Levy, R. et al. SD-101, a novel class C CpG-oligodeoxynucleotide (ODN) Toll-like receptor 9 (TLR9) agonist, given with low dose radiation for untreated low grade B-cell lymphoma: interim results of a phase 1/2 trial. <i>Blood</i> <b>128</b>, 2974 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood.V128.22.2974.2974" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.V128.22.2974.2974" aria-label="Article reference 179" data-doi="10.1182/blood.V128.22.2974.2974">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 179" href="http://scholar.google.com/scholar_lookup?&amp;title=SD-101%2C%20a%20novel%20class%20C%20CpG-oligodeoxynucleotide%20%28ODN%29%20Toll-like%20receptor%209%20%28TLR9%29%20agonist%2C%20given%20with%20low%20dose%20radiation%20for%20untreated%20low%20grade%20B-cell%20lymphoma%3A%20interim%20results%20of%20a%20phase%201%2F2%20trial&amp;journal=Blood&amp;doi=10.1182%2Fblood.V128.22.2974.2974&amp;volume=128&amp;publication_year=2016&amp;author=Levy%2CR">
                    Google Scholar</a> 
                </p></li></div></div>
  </body>
</html>
